<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">21735</article-id><article-id pub-id-type="doi">10.7554/eLife.21735</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Lack of IL-1R8 in neurons causes hyperactivation of IL-1 receptor pathway and induces MECP2-dependent synaptic defects</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-69159"><name><surname>Tomasoni</surname><given-names>Romana</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3374-2698</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="data-ro1"/></contrib><contrib contrib-type="author" id="author-70244"><name><surname>Morini</surname><given-names>Raffaella</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-70245"><name><surname>Lopez-Atalaya</surname><given-names>Jose P</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="data-ro1"/></contrib><contrib contrib-type="author" id="author-70246"><name><surname>Corradini</surname><given-names>Irene</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-70247"><name><surname>Canzi</surname><given-names>Alice</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-70248"><name><surname>Rasile</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-80924"><name><surname>Mantovani</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-80925"><name><surname>Pozzi</surname><given-names>Davide</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-68783"><name><surname>Garlanda</surname><given-names>Cecilia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-43111"><name><surname>Mantovani</surname><given-names>Alberto</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-70249"><name><surname>Menna</surname><given-names>Elisabetta</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35776"><name><surname>Barco</surname><given-names>Angel</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="data-ro1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-69165"><name><surname>Matteoli</surname><given-names>Michela</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3569-7843</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-9"/><xref ref-type="other" rid="par-10"/><xref ref-type="other" rid="par-11"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="data-ro1"/></contrib><aff id="aff1"><label>1</label><institution>IRCCS Humanitas</institution>, <addr-line><named-content content-type="city">Rozzano</named-content></addr-line>, <country>Italy</country></aff><aff id="aff2"><label>2</label><institution>Instituto de Neurociencias (Universidad Miguel Hernández-Consejo Superior de Investigaciones Científicas)</institution>, <addr-line><named-content content-type="city">Alicante</named-content></addr-line>, <country>Spain</country></aff><aff id="aff3"><label>3</label><institution>IN-CNR</institution>, <addr-line><named-content content-type="city">Milano</named-content></addr-line>, <country>Italy</country></aff><aff id="aff4"><label>4</label><institution>Hunimed University</institution>, <addr-line><named-content content-type="city">Rozzano</named-content></addr-line>, <country>Italy</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Goda</surname><given-names>Yukiko</given-names></name><role>Reviewing editor</role><aff id="aff5"><institution>RIKEN</institution>, <country>Japan</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>michela.matteoli@humanitasresearch.it</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>28</day><month>03</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>6</volume><elocation-id>e21735</elocation-id><history><date date-type="received"><day>23</day><month>09</month><year>2016</year></date><date date-type="accepted"><day>26</day><month>02</month><year>2017</year></date></history><permissions><copyright-statement>© 2017, Tomasoni et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Tomasoni et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-21735-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.21735.001</object-id><p>Inflammation modifies risk and/or severity of a variety of brain diseases through still elusive molecular mechanisms. Here we show that hyperactivation of the interleukin 1 pathway, through either ablation of the interleukin 1 receptor 8 (IL-1R8, also known as SIGIRR or Tir8) or activation of IL-1R, leads to up-regulation of the mTOR pathway and increased levels of the epigenetic regulator MeCP2, bringing to disruption of dendritic spine morphology, synaptic plasticity and plasticity-related gene expression. Genetic correction of MeCP2 levels in IL-1R8 KO neurons rescues the synaptic defects. Pharmacological inhibition of IL-1R activation by Anakinra corrects transcriptional changes, restores MeCP2 levels and spine plasticity and ameliorates cognitive defects in IL-1R8 KO mice. By linking for the first time neuronal MeCP2, a key player in brain development, to immune activation and demonstrating that synaptic defects can be pharmacologically reversed, these data open the possibility for novel treatments of neurological diseases through the immune system modulation.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.001">http://dx.doi.org/10.7554/eLife.21735.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.21735.002</object-id><title>eLife digest</title><p>Errors that occur while the brain is developing can lead to conditions such as autism and schizophrenia. They can also lead to rare disorders like Rett syndrome and MeCP2 duplication syndromes, which are characterized by severe cognitive and physical disabilities. Many people with these neurodevelopmental disorders have mutations in genes that encode proteins found at synapses, which are the junctions between neurons where the cells exchange information with one another. However, not everyone with these mutations develops a neurodevelopmental disorder, which indicates that other, non-genetic factors also play a part.</p><p>One of the main non-genetic factors that can influence the risk and severity of neurodevelopmental disorders is inflammation of the brain. Inflammation is a normal part of the body’s immune response to threats such as invading microorganisms or tissue damage. However, abnormal activation of the immune system in early life can trigger excessive inflammation. This increases the risk of a neurodevelopmental disorder, but it is not clear exactly how it does so.</p><p>Tomasoni et al. set out to test whether the missing link between inflammation and neurodevelopmental disorders might be damage to synapses. The experiments revealed that genetically modified mice with inflammation of the brain have abnormal synapses and are unable to learn properly. These mutant mice also have excessive levels of a protein that influences how synapses function called MeCP2, which is missing in the brains of people with Rett syndrome and abnormally increased in brains of patients affected by MeCP2 Duplication Syndrome. This is thus the first evidence that directly links inflammation of the brain to a synapse protein implicated in a disorder of brain development.</p><p>Tomasoni et al. also found that a drug called anakinra – which is used to treat an inflammatory disease called rheumatoid arthritis – reduced levels of MeCP2 in the mutant mice and improved their performance in cognitive tasks. Together, these results raise the possibility that anti-inflammatory medications may be beneficial in the treatment of neurodevelopment disorders.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.002">http://dx.doi.org/10.7554/eLife.21735.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>Neuroimmunology</kwd><kwd>synaptic plasticity</kwd><kwd>MeCP2</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002803</institution-id><institution>Fondazione Cariplo</institution></institution-wrap></funding-source><award-id>2015-0952</award-id><principal-award-recipient><name><surname>Tomasoni</surname><given-names>Romana</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002803</institution-id><institution>Fondazione Cariplo</institution></institution-wrap></funding-source><award-id>2015–0952</award-id><principal-award-recipient><name><surname>Tomasoni</surname><given-names>Romana</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003329</institution-id><institution>Ministerio de Economía y Competitividad</institution></institution-wrap></funding-source><award-id>SAF2014-60233-JIN</award-id><principal-award-recipient><name><surname>Lopez-Atalaya</surname><given-names>Jose P</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Fondazione Giancarla Vollaro</institution></institution-wrap></funding-source><award-id>Fellowship</award-id><principal-award-recipient><name><surname>Corradini</surname><given-names>Irene</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002803</institution-id><institution>Fondazione Cariplo</institution></institution-wrap></funding-source><award-id>2015-0564</award-id><principal-award-recipient><name><surname>Mantovani</surname><given-names>Alberto</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003329</institution-id><institution>Ministerio de Economía y Competitividad</institution></institution-wrap></funding-source><award-id>SAF2014-56197-R</award-id><principal-award-recipient><name><surname>Barco</surname><given-names>Angel</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003329</institution-id><institution>Ministerio de Economía y Competitividad</institution></institution-wrap></funding-source><award-id>SEV-2013-0317</award-id><principal-award-recipient><name><surname>Barco</surname><given-names>Angel</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003329</institution-id><institution>Ministerio de Economía y Competitividad</institution></institution-wrap></funding-source><award-id>PCIN-2015-192-C02-01</award-id><principal-award-recipient><name><surname>Barco</surname><given-names>Angel</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002803</institution-id><institution>Fondazione Cariplo</institution></institution-wrap></funding-source><award-id>2015-0594</award-id><principal-award-recipient><name><surname>Matteoli</surname><given-names>Michela</given-names></name></principal-award-recipient></award-group><award-group id="par-10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003196</institution-id><institution>Ministero della Salute</institution></institution-wrap></funding-source><award-id>GR-2011-02347377</award-id><principal-award-recipient><name><surname>Matteoli</surname><given-names>Michela</given-names></name></principal-award-recipient></award-group><award-group id="par-11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002803</institution-id><institution>Fondazione Cariplo</institution></institution-wrap></funding-source><award-id>2012-0560</award-id><principal-award-recipient><name><surname>Matteoli</surname><given-names>Michela</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Excessive inflammation of the brain in early life predisposes individuals to neurodevelopmental disorders by preventing synapses from developing correctly.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Neurological disorders represent an enormous source of burden to the individual and to society, with many patients failing to respond to available medication. Growing evidence on genetic components of neurological diseases have been collected during recent years; notably, these genes overwhelmingly point to disorders of synaptic transmission, which led to the coinage of the term ‘synaptopathy’ to indicate a brain disease originating from a dysfunction of the synapse (<xref ref-type="bibr" rid="bib33">Grant, 2012</xref>; <xref ref-type="bibr" rid="bib32">Grabrucker, 2014</xref>). Disruption of synapse function may also be caused by environmental stimuli, with inflammatory cytokines affecting synaptic transmission and modifying the risk and severity of a variety of brain diseases, including autism spectrum disorders, schizophrenia and cognitive disabilities (<xref ref-type="bibr" rid="bib36">Hagberg et al., 2012</xref>; <xref ref-type="bibr" rid="bib14">Chugh et al., 2013</xref>; <xref ref-type="bibr" rid="bib78">Steinman, 2013</xref>). Among the cytokines known to affect synaptic function, the proinflammatory cytokine IL-1β plays a critical role. IL-1β was found to impair brain-derived neurotrophic factor (BDNF)-induced expression of molecules critical for activity-dependent synaptic plasticity, including cAMP response element binding protein (CREB), Arc, and cofilin, thus reducing actin polymerization and impairing spine morphogenesis (<xref ref-type="bibr" rid="bib81">Tong et al., 2012</xref>). In addition, IL-1β controls different neuronal functions, including excitability and transmitter release, via multiple biochemical pathways (<xref ref-type="bibr" rid="bib87">Weber et al., 2010</xref>). However, no evidence has been reported yet that IL-1β may affect synapse development and function acting on molecular pathways known to be at the root of synaptopathies.</p><p>Genetic mouse models of immune deregulation may serve as reliable and reproducible systems for examination of the effects of inflammation on synapse structure and function and elucidation of the molecular processes involved. IL-1R8, also known as single Ig IL-1-Related Receptor (SIGIRR) or TIR8, belongs to the toll-like receptors (TLRs) and interleukin-1R-like receptors (ILRs), a family of conserved proteins involved in immunity and inflammation (<xref ref-type="bibr" rid="bib72">Riva et al., 2012</xref>; <xref ref-type="bibr" rid="bib26">Garlanda et al., 2013a</xref>). TLRs are receptors able to recognize specific pathogen-associated patterns (PAMPs) and necrotic cell-derived danger signals (DAMPs) and act as sensors for microorganisms and tissue damage, whereas the IL-1R subfamily includes components of signalling receptor complexes as well as molecules with regulatory function. IL-1R8 dampens the activation of the TLRs and IL-1R signalling pathways by intracellularly interfering with the association of adaptor molecules to the receptor complexes, including NF-κB and JNK (<xref ref-type="bibr" rid="bib72">Riva et al., 2012</xref>; <xref ref-type="bibr" rid="bib27">Garlanda et al., 2013b</xref>). As a consequence, IL-1R8-deficient mice display exaggerated symptoms of inflammatory conditions (<xref ref-type="bibr" rid="bib29">Garlanda et al., 2007</xref>; <xref ref-type="bibr" rid="bib34">Gulen et al., 2010</xref>; <xref ref-type="bibr" rid="bib23">Drexler et al., 2010</xref>) and demonstrate pronounced susceptibility to the inflammatory challenge posed by microbial LPS (<xref ref-type="bibr" rid="bib28">Garlanda et al., 2004</xref>). IL-1R8 is also present in the brain (<xref ref-type="bibr" rid="bib19">Costelloe et al., 2008</xref>; <xref ref-type="bibr" rid="bib67">Polentarutti et al., 2003</xref>). Genetic deficiency for IL-1R8 is associated with inflammatory changes in the brain, including increased levels of LPS-induced tumor necrosis factor α (TNFα) and IL-6 in microglia, higher expression of TLR4, and NF-κB activation (<xref ref-type="bibr" rid="bib86">Watson et al., 2010</xref>). Reduced IL-1R8 expression has been described in patients affected by psoriatic arthritis (<xref ref-type="bibr" rid="bib6">Batliwalla et al., 2005</xref>) while SIGIRR variants (characterized by defective SIGIRR function) have been found in humans in association with necrotizing enterocolitis (<xref ref-type="bibr" rid="bib75">Sampath et al., 2015</xref>) and with systemic lupus erythematosus (SLE; [<xref ref-type="bibr" rid="bib92">Zhu et al., 2014</xref>]), all pathologies being characterized by cognitive defects and neurodevelopmental impairment (<xref ref-type="bibr" rid="bib39">Husted et al., 2013</xref>; <xref ref-type="bibr" rid="bib70">Rees et al., 2007</xref>; <xref ref-type="bibr" rid="bib10">Calderón et al., 2014</xref>; <xref ref-type="bibr" rid="bib59">Muscal et al., 2010</xref>). Notably, IL-1R8-deficient mice are impaired in novel object recognition, spatial reference memory and long-term potentiation (LTP), defects that occur in the absence of any external inflammatory stimuli (<xref ref-type="bibr" rid="bib18">Costello et al., 2011</xref>). However, the molecular mechanisms by which IL-1R8 deficiency results in brain defects are still completely unknown.</p><p>We used IL-1R8 deficient mice to investigate whether genetic hyperactivation of the IL-1R pathway affects synapse function impinging on molecular players involved in synaptopathies. We demonstrate that the activity of the IL-1R pathway directly affects, in neurons, the levels of expression of the methyl-CpG-binding protein 2 (MeCP2), a synaptopathy protein involved in neurological diseases -Rett syndrome and MeCP2 duplication syndrome- characterized by defective plasticity, impaired cognition and intellectual disability. We also show that pharmacological inhibition of IL-1R activity normalizes MeCP2 expression and cognitive deficits in IL1R8-deficient mice.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Altered synaptic architecture and function in IL-1R8 KO hippocampal neurons</title><p>To investigate the impact of IL-1R8 deficiency on synapse structure and function, we examined the morphology and plasticity of dendritic spines in primary cultures established from embryonic IL-1R8 KO or WT mice hippocampi, transfected with GFP at DIV 12. Compared to their WT counterpart, IL-1R8 KO neurons displayed an increased number of immature, thin spines and a decreased number of mature, mushroom spines (<xref ref-type="fig" rid="fig1">Figure 1A–C</xref>) along with a significant reduction of spine width (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Also PSD-95 puncta density (<xref ref-type="fig" rid="fig1">Figure 1E</xref>) and size (<xref ref-type="fig" rid="fig1">Figure 1F</xref>) were significantly lower in IL-1R8 KO neurons. Consistently, the levels of the postsynaptic protein PSD-95, evaluated by western blotting of culture homogenates were significantly reduced (<xref ref-type="fig" rid="fig1">Figure 1G and H</xref>). In line with a synaptic defect, patch clamp recording of IL-1R8 deficient cultures revealed that the frequency, but not the amplitude, of miniature excitatory postsynaptic currents (mEPSCs) was significantly reduced (<xref ref-type="fig" rid="fig1">Figure 1I–K</xref>). Spine defects (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>) and reduction in synaptic markers (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>) were also detected in CA1 pyramidal neurons of IL1R8 KO mice with respect to age-matched WT controls.<fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.21735.003</object-id><label>Figure 1.</label><caption><title>IL-1R8 silencing affects spine morphology and function.</title><p>(<bold>A</bold>) PSD-95 immunocytochemical staining of GFP-transfected, 16 DIV hippocampal cultures from WT or IL-1R8 KO mice. Scale bar 5 mm. (<bold>B-F</bold>) Quantitative analysis of the following parameters: thin and mushroom spine density (<bold>B</bold> and <bold>C</bold>); spine width (<bold>D</bold>); PSD-95 puncta density (<bold>E</bold>) and mean size of PSD-95 puncta (<bold>F</bold>). Number of analyzed neurons: <bold>B-D</bold>: 32 (WT), 44 (IL-1R8 KO); <bold>E-F</bold>: 32 (WT), 29 (IL-1R8 KO); Student t test. (<bold>G, H</bold>) Western blotting analysis of PSD-95 levels in primary hippocampal cultures, 3 independent experiments, Mann Whitney test. (<bold>I</bold>) Representative mEPSC traces recorded from WT and IL-1R8 KO neurons. (<bold>J</bold>) mEPSC frequency quantitation (WT: n = 12; IL-1R8 KO: n = 18; Mann Whitney Test). (<bold>K</bold>) Cumulative distributions and bar graph of mEPSC amplitude (WT: 22,82 ± 2, n = 12; IL-1R8 KO: 22,11 ± 1,5, n = 18; Mann Whitney test. * indicates significance compared to WT, # indicates, significance compared to IL-1R8 KO.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.003">http://dx.doi.org/10.7554/eLife.21735.003</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21735-fig1-v1"/></fig><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.21735.004</object-id><label>Figure 2.</label><caption><title>IL1R8 deficient mice show altered spines and synapses in hippocampal sections.</title><p>(<bold>A</bold>) Representative images of secondary branches of apical dendrites of WT and IL-1R8 KO mice (3 months old) stained by the Golgi-Cox method and relative quantitation (<bold>B</bold>). A significant reduction of spine density in IL-1R8 KO mice was evident with respect to WT mice (number of spines per micron: WT = 1,02 ± 0,03; number of mice analyzed: 3, number of examined dendrites: 75; IL-1R8 KO = 0,80 ± 0,02; number of mice analyzed: 3, number of examined dendrites: 84; Mann-Whitney test). Scale bar, 5 µm. (<bold>C</bold>) Representative fields of the CA1 hippocampal region (stratum radiatum) of a WT and IL-1R8 KO mouse brain (1 month old mice), stained for the vesicular glutamate transporter, vGLUT1. Scale bar, 15 µm. (<bold>D</bold>) A significant reduction in vGLUT1 area was found in the stratum radiatum of CA1 field of IL-1R8 KO mice (total area of vGLUT1 positive puncta WT = 0,4644 ± 0,03420; number of examined fields: 35; IL-1R8 KO = 0,2910 ± 0,01984; number of examined fields: 47; Mann-Whitney test).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.004">http://dx.doi.org/10.7554/eLife.21735.004</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21735-fig2-v1"/></fig></p><p>To investigate whether IL-1R8 KO neurons are able to undergo synaptic potentiation, hippocampal cultures were subjected to an established chemical LTP (c-LTP) protocol based on the culture exposure to 100 μM glycine in KRH devoid of Mg, followed by a washout and recovery in neuronal medium for at least 60 min (<xref ref-type="bibr" rid="bib54">Menna et al., 2013</xref>). Under these conditions, a significant increase in the density of both PSD-95-positive puncta and mushroom spines occurred in WT but not in IL-1R8 KO neurons (<xref ref-type="fig" rid="fig3">Figure 3A–C</xref>). Similarly, no increase in mEPSC amplitude and frequency was recorded over time in IL-1R8 KO neurons (<xref ref-type="fig" rid="fig3">Figure 3D–F</xref>), univocally indicating that hippocampal IL-1R8 KO neurons are unable to undergo synaptic plasticity. These data show the occurrence of synaptic structural and functional defects in primary cultures from IL-1R8 KO mice.<fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.21735.005</object-id><label>Figure 3.</label><caption><title>IL-1R8 KO neurons do not undergo LTP.</title><p>(<bold>A</bold>) PSD-95 immunocytochemical staining of GFP-transfected, DIV 16 hippocampal cultures from WT or IL-1R8 KO mice, subjected or not to the LTP protocol. Scale bar 5 μm. (<bold>B</bold> and <bold>C</bold>) Quantitative analysis of PSD-95 and mushroom spine density of neurons treated as above. Number of analyzed neurons, B: 15 (WT, no LTP), 13 (WT, + LTP), 28 (IL-1R8 KO, no LTP), 18 (IL-1R8 KO, + LTP); C: 16 (WT, no LTP), 33 (WT, + LTP), 24 (IL-1R8 KO, no LTP), 34 (IL-1R8 KO, + LTP); one-way ANOVA analysis of variance followed by post hoc Tukey test). (<bold>D</bold>) Representative traces of mEPSCs recorded from neurons of WT or IL-1R8 KO mice before and 60 min after LTP induction. (<bold>E</bold> and <bold>F</bold>) Averaged mEPSC frequency and amplitude of WT and IL-1R8 KO neurons over different recording time points after LTP induction. Normalized mEPSC frequency: WT 0 min: 0,99 ± 0,06, n = 11; 20 min 1,84 ± 0,3, n = 12; 60 min 1,81 ± 0,14, n = 9; IL-1R8 KO 0 min 1,0 ± 0,07, n = 10; 20 min 1,11 ± 0,15, n = 11; 60 min 0,94 ± 0,07, n = 5. Normalized mEPSC amplitude: WT 0 min: 0,99 ± 0,03, n = 11; 20 min 1,29 ± 0,14, n = 12; 60 min 1,36 ± 0,14, n = 9; IL-1R8 KO 0 min 0,96 ± 0,05, n = 10; 20 min 0,91 ± 0,07, n = 11; 60 min 0,99 ± 0,1, n = 5. Mann Whitney test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.005">http://dx.doi.org/10.7554/eLife.21735.005</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21735-fig3-v1"/></fig></p></sec><sec id="s2-2"><title>Defects in the structure and function of IL-1R8 KO neurons are reversed by blocking IL-1 receptor activity</title><p>To determine whether the synaptic defects of IL-1R8 KO neurons are attributable to IL-1 receptor (IL-1R) or TLR pathway, both negatively regulated by IL-1R8, we analyzed spine density and electrophysiological properties in neurons from mice deficient for both IL-1R8 and IL-1R (IL-1R8 KO IL-1R KO). Double IL-1R8 KO IL-1R KO neurons displayed an increase in mushroom spine density (number of spines/micron, mean ± SEM, WT: 0,1581 ± 0,01508, n = 32; IL-1R8 KO IL-1R KO: 0,2585 ± 0,0154, n = 41, Student t test, p&lt;0,0001), accompanied by enhanced mEPSCs frequency and amplitude (mEPSC frequency, mean ± SEM, WT: 1317 ± 0,1714, n = 12; IL-1R8 KO IL-1R KO: 2432 ± 0,3187, n = 17, Student t test, p&lt;0,05; mEPSC amplitude, mean + SEM, WT: 22,82 ± 2468, n = 12; IL-1R8 KO IL-1R KO: 29,10 ± 2112, n = 17, Student t test, ns, p=0,0644). These data suggest a role for IL-1R signaling in controlling synaptic structure and function. To determine if reducing IL-1R activity could restore synaptic plasticity and spatial learning, hippocampal neurons from IL-1R8 KO mice exposed overnight to IL1Ra (Anakinra), a naturally-occurring IL-1 receptor antagonist (<xref ref-type="bibr" rid="bib22">Dinarello, 2009</xref>), displayed increased density of both mushroom spines (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>) and PSD-95 puncta (<xref ref-type="fig" rid="fig4">Figure 4A and C</xref>). Furthermore, IL1Ra-treated neurons from IL-1R8 KO mice recovered their ability to undergo both structural and functional LTP, as indicated by the increased density of spines and PSD-95 (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>) and mEPSC frequency and amplitude (<xref ref-type="fig" rid="fig4">Figure 4D–F</xref>) following the application of the c-LTP protocol. Therefore, the IL-1R8 KO synaptic phenotype results from hyperactivation of the IL-1R pathway as a result of IL-1R8 silencing. Consistently, pharmacological activation of IL-1R pathway in WT neurons through overnight treatment with IL-1β (40 ng/ml for 14 hr) resulted in an increased number of immature thin spines and a decreased number of mature mushroom-type spines (<xref ref-type="fig" rid="fig4">Figure 4G–I</xref>) and PSD-95 puncta (<xref ref-type="fig" rid="fig4">Figure 4G and J</xref>), accompanied by inability to undergo LTP (<xref ref-type="fig" rid="fig4">Figure 4G–J</xref>).<fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.21735.006</object-id><label>Figure 4.</label><caption><title>Inhibition of IL-1R signalling restores LTP in IL-1R8 KO neurons.</title><p>(<bold>A</bold>) PSD-95 immunocytochemical staining of 16 DIV hippocampal cultures from GFP transfected WT or IL-1R8 KO mice, treated or not, at DIV 15 with IL1Ra (20 ng/ml) overnight (14 hr). Scale bar 5 μm. (<bold>B</bold>) Quantitative analysis of mushroom spine density in control or upon LTP protocol application. Similar results were obtained with IL1Ra at 100 ng/ml. Number of analyzed neurons: 14 (WT, no LTP), 16 (WT, + LTP), 10 (WT, IL1Ra, no LTP), 10 (WT, IL1Ra, + LTP), 26 (IL-1R8 KO, no LTP), 29 (IL-1R8 KO, + LTP), 23 (IL-1R8 KO, IL1Ra, no LTP), 32 (IL-1R8 KO, IL1Ra, + LTP); one-way ANOVA analysis of variance followed by post hoc Tukey test). (<bold>C</bold>) Quantitative analysis of PSD-95 immunoreactivity. Number of analyzed neurons: 9 (WT, no LTP), 26 (WT, + LTP), 27 (WT, IL1Ra, no LTP), 24 (WT, IL1Ra, + LTP), 24 (IL-1R8 KO, no LTP), 62 (IL-1R8 KO, + LTP), 13 (IL-1R8 KO, IL1Ra, no LTP), 12 (IL-1R8 KO, IL1Ra, + LTP). One-way ANOVA analysis of variance followed by post hoc Tukey test. (<bold>D</bold>) Representative traces of WT and IL-1R8 KO neurons treated with vehicle or IL1Ra (100 ng/ml). (<bold>E</bold> and <bold>F</bold>) Quantitation of mEPSC frequency and amplitude recorded 60 min after LTP protocol in WT or IL-1R8 KO neurons, treated as above. Analysis of normalized mEPSC frequency and amplitude reveals that only WT neurons and IL1-Ra-treated IL-1R8 KO neurons undergo LTP. Number of recorded neurons: 6 (WT, no LTP), 6 (WT, + LTP), 8 (WT, IL1Ra, no LTP), 8 (WT, IL1Ra, + LTP), 9 (IL-1R8 KO, no LTP), 6 (IL-1R8 KO, + LTP), 8 (IL-1R8 KO, IL1Ra, no LTP), 12 (IL-1R8 KO, IL1Ra, + LTP), Mann-Whitney test. (<bold>G</bold>) Immunocytochemical staining for PSD-95 in GFP-transfected WT neurons treated or not with IL-1β (40 ng/ml, overnight) and subjected or not to LTP stimulation. Scale bar 5 μm. (<bold>H</bold> and <bold>I</bold>) Quantitative analysis of mushroom and thin spine density. Number of analyzed neurons: 14 (WT, no LTP), 16 (WT, + LTP), 28 (WT, IL-1β, no LTP), 27 (WT, IL-1β, + LTP), one-way ANOVA analysis of variance followed by post hoc Tukey test. (<bold>J</bold>) Quantitative analysis of PSD-95 density. Number of analyzed neurons: 9 (WT, no LTP), 13 (WT, + LTP), 15 (WT, IL-1β, no LTP), 15 (WT, IL-1β, + LTP), one-way ANOVA analysis of variance followed by post hoc Tukey test. Data indicate that application of IL-1β prevents synaptic potentiation.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.006">http://dx.doi.org/10.7554/eLife.21735.006</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21735-fig4-v1"/></fig></p><p>Of note, exposure of WT neurons to IL-1Ra prevented LTP, as assessed by confocal analysis (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>) or electrophysiological recording (<xref ref-type="fig" rid="fig4">Figure 4D–F</xref>), indicating that IL-1R acts positively in supporting LTP, even when IL-1R8 expression is not perturbed. In line with these observations, we found that neurons genetically devoid of IL-1 receptor (IL-1R KO) were unable to undergo plasticity phenomena (mushroom spine density: WT, no LTP: 0,13 ± 0009, n = 19; WT, + LTP: 0,36 ± 0,03, n = 18; Student t test, p&lt;00001. IL-1R KO, no LTP: 0,41 ± 0,03; IL-1R KO, + LTP: 0,49 ± 0,03 n = 18; Student t test, p ns = 0,1024). Therefore, in line with literature data (<xref ref-type="bibr" rid="bib18">Costello et al., 2011</xref>; <xref ref-type="bibr" rid="bib77">Schneider et al., 1998</xref>; <xref ref-type="bibr" rid="bib16">Coogan and O'Connor, 1999</xref>; <xref ref-type="bibr" rid="bib4">Avital et al., 2003</xref>), either pharmacological or genetic silencing of IL-1R is per se sufficient to alter dendritic spine morphology and plasticity, indicating that physiological levels of IL-1R activation are required for correct long-term potentiation.</p></sec><sec id="s2-3"><title>IL-1β treatment and IL-1R8 deficiency trigger overlapping gene programs related to hippocampal development and synaptic transmission</title><p>To further dissect changes in WT, IL-1R8 KO and WT mice treated with IL-1β, we conducted transcriptomic analysis on cortical tissues. RNA-seq data revealed that genetic ablation of IL-1R8 and pharmacological activation of IL-1R both lead to altered transcription of a shared subset of genes (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). Treatment of WT mice with IL-1β led to transcriptional alterations in 1084 genes (60.6% downregulated and 39.4% upregulated, <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1</xref>). IL-1R8 KO mice showed alterations in expression of 639 genes compared to WT (49.1% downregulated and 50.9% upregulated, <xref ref-type="supplementary-material" rid="SD2-data">Supplementary file 2</xref>). Comparing the two sets of genes, we observed a highly significant overlap of 193 genes whose expression was altered by either IL-1β treatment and IL-1R8 deficiency (Fischer’s exact test; P value = 2.2e-16; Pearson correlation coefficient = 0.95; 61.7% downregulated and 38.3% upregulated, <xref ref-type="supplementary-material" rid="SD3-data">Supplementary file 3</xref>). Gene Ontology (GO) enrichment analysis revealed that the deregulated genes are clustered in specific categories referring to biological processes such as <italic>hippocampal development</italic> and <italic>synaptic transmission</italic>, among others (<xref ref-type="supplementary-material" rid="SD4-data">Supplementary file 4</xref>). Moreover, consistent with our results in neuronal cultures, transcriptomic analysis of IL-1R8 KO mice treated with Anakinra revealed that this pharmacological treatment largely reversed the transcriptional alterations observed in IL-1R8 KO mice (83.1%; False Discovery Rate/FDR &lt;0.1; 80.8%, FDR &lt; 0.05), including most of the shared changed genes between IL-1R8 KO mice and in IL1β stimulated mice (89.0%; FDR &lt; 0.1; 88.7%, FDR &lt; 0.05) (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> and <xref ref-type="supplementary-material" rid="SD3-data">Supplementary file 3</xref>). Notably, the reversion affected important synaptic genes downregulated in both IL-1R8 KO and IL-1β-treated mice, such as <italic>Mdga1</italic> (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>), <italic>Cnih2</italic> and <italic>Sez6</italic> (<xref ref-type="supplementary-material" rid="SD3-data">Supplementary file 3</xref>). These data indicate that acute IL-1β treatment and IL-1R8 deficiency trigger overlapping gene programs which are reversed, in the case of IL-1R8 KO mice, by acute exposure to Anakinra.<fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.21735.007</object-id><label>Figure 5.</label><caption><title>Transcriptomic analysis of cortices from WT mice treated with IL-1β and IL-1R8 KO mice reveals common genes with altered regulation, and reversal of altered expression upon treatment of IL-1R8 KO mice with the IL-1β antagonist Anakinra.</title><p>(<bold>A</bold>) Venn diagram showing significant overlap in the number of Differentially Expressed (DE) genes between conditions (P value = 2.2e-16, Fischer’s exact test). IL1β labels DE genes after IL1β administration and IL-1R8 KO show DE genes in IL-1R8 KO mice. (<bold>B</bold>) Heatmap showing a hierarchical clustering of the genes (rows) based on fold changes of expression in each sample versus the average level in the WT condition. Color sidebar for the samples is indicative of the condition: WT (black), treatment with IL-1β (green), or IL-1R8 KO (orange). The inset key shows the color scale of the fold change matrix (log2 values), from blue (downregulated genes) to red (upregulated genes), and white for non-regulated genes. (<bold>C</bold>) Line chart showing fold change (log2 values) against condition (IL1β, IL-1R8 KO, IL-1R8 KO + Anakinra) for DE genes in IL-1R8 KO mice (FDR &lt; 0.1) and also upon IL1β administration to WT mice (FDR &lt; 0.1, 193 genes). Genes that were reversed upon treatment of IL-1R8 KO mice with Anakinra are shown in red (96 upregulated genes) or blue (60 downregulated genes). Genes that were not reversed by Anakinra are shown in light grey (37 genes). (<bold>D</bold>) Bar graph showing the absolute number of genes that were either reversed or non-affected by treatment of IL-1R8 KO mice with Anakinra. Percentage of reversed genes over the total of DE genes in each gene list is also shown. DE gene lists are as follows: IL-1R8 KO FDR &lt; 0.1 (639 genes); IL-1R8 KO FDR &lt; 0.05 (264 genes); IL-1R8 KO ∩ IL1β FDR &lt; 0.1 (193 genes); IL-1R8 KO ∩ IL1β FDR &lt; 0.05 (71 genes). Reversed genes are defined as not found to be DE using the indicated significance threshold in each group, in the comparison of IL-1R8 KO + Anakinra versus WT mice, and those that were differentially expressed in this comparison but in the opposite direction found in IL1β and IL-1R8 KO conditions.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.007">http://dx.doi.org/10.7554/eLife.21735.007</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21735-fig5-v1"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.21735.008</object-id><label>Figure 5—figure supplement 1.</label><caption><title>RNA-seq profiles in the cortex of WT, WT treated with IL-1β, IL-1R8 KO mice, and IL-1R8 KO mice treated with Anakinra.</title><p>RNA-seq profiles at the Mdga1 locus presenting downregulation of transcript levels in WT mice in response to IL-1β treatment. Transcript levels for Mdga1 are also reduced in the cortex of IL-1R8 KO mice. Administration of Anakinra to IL-1R8 KO mice restored Mdga1 transcript levels to that of WT ones. Note the very high reproducibility of the profiles between samples. Mdga1 is involved in maintaining the proper balance between excitatory and inhibitory synapses (<xref ref-type="bibr" rid="bib66">Pettem et al., 2013</xref>).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.008">http://dx.doi.org/10.7554/eLife.21735.008</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21735-fig5-figsupp1-v1"/></fig></fig-group></p></sec><sec id="s2-4"><title>IL-1R effects on hippocampal synapses are mediated by the PI3K/AKT/mTOR pathway</title><p>We next identified the downstream signaling pathway through which hyperactivation of the IL-1R pathway in IL-1R8 KO neurons influences spine morphology and function. The signaling pathways downstream of IL-1R8 have been described in non-neuronal cells and found to include i) the inhibition of NF-κB and JNK activation, dependent on IL-Rs or TLRs family member activation and ii) the IL-1-dependent activation of the Akt-mTOR pathway (reviewed in <xref ref-type="bibr" rid="bib72">Riva et al. [2012]</xref>). Based on the known involvement of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway in the induction and maintenance of LTP in different brain regions (<xref ref-type="bibr" rid="bib64">Opazo et al., 2003</xref>; <xref ref-type="bibr" rid="bib49">Lee et al., 2011</xref>), we focused on the possibility that the lack of IL-1R8 could result in the hyperactivation of this pathway. This possibility would be in line with the demonstrated cognitive and plasticity deficits occurring in genetic mouse models characterized by increased mTOR signaling (reviewed in <xref ref-type="bibr" rid="bib38">Hoeffer and Klann [2010]</xref>). Overnight treatment of 15 DIV IL-1R8 KO neurons with 20 nM rapamycin (<xref ref-type="bibr" rid="bib85">Vézina et al., 1975</xref>), which inhibits both mTORC1 and mTORC2, was sufficient to reverse the defective spine phenotype, with IL-1R8 KO treated neurons displaying an increase in density of both mushroom spines (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>) and PSD-95 puncta (<xref ref-type="fig" rid="fig6">Figure 6A and C</xref>) relative to untreated IL-1R8 KO neurons. Similarly, overnight exposure to 30 μM LY294002, a specific inhibitor of PI3K, or 20 nM wortmannin, a PI3-K/Akt signal transduction inhibitor, rescued mushroom spine and PSD-95 densities in IL-1R8 KO neurons (<xref ref-type="fig" rid="fig6">Figure 6</xref>). None of the blockers produced damage to the neurons, at least for the time of incubation used. These data demonstrate that hyperactivation of IL-1R in IL-1R8 KO neurons impairs spine morphogenesis and plasticity through the PI3K/AKT/mTOR pathway. Again, WT neurons exposed to the different inhibitors displayed an increase in spine and postsynaptic marker density (<xref ref-type="fig" rid="fig6">Figure 6A–C</xref>). These data indicate that the endogenous activation of mTOR/PI3K/Akt pathway, like already shown for IL-1R activation (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>), is required for correct spine morphogenesis.<fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.21735.009</object-id><label>Figure 6.</label><caption><title>Inhibition of mTOR signalling restores LTP in IL-1R8 KO neurons.</title><p>(<bold>A</bold>) PSD-95 immunocytochemical staining of GFP-transfected 16 DIV hippocampal cultures from WT or IL-1R8 KO mice. At DIV 15 neurons were treated with rapamycin (Rapa, 20 nM), LY294002 (LY, 30 μM) or wortmannin (wort, 20 nM) overnight (14 hr). Scale bar, 5 μm. (<bold>B</bold>) Quantitative analysis of mushroom spine density. Number of analyzed neurons: 36 (WT), 17 (WT, Rapa), 10 (WT, LY), 5 (WT, Wort), 42 (IL-1R8 KO), 35 (IL-1R8 KO, Rapa), 28 (IL-1R8 KO, LY), 30 (IL-1R8 KO, Wort); one-way ANOVA analysis of variance followed by post hoc Tukey test. (<bold>C</bold>) Quantitative analysis of PSD-95 puncta density. Number of analyzed neurons: 17 (WT), 7 (WT, Rapa), 9 (WT, LY), 11 (WT, Wort), 9 (IL-1R8 KO), 15 (IL-1R8 KO, Rapa), 15 (IL-1R8 KO, LY), 18 (IL-1R8 KO, Wort); one-way ANOVA analysis of variance followed by post hoc Tukey test. Data indicate that inhibitors of the mTOR pathway restore synaptic potentiation. * indicates significance compared to WT, # indicates significance compared to IL-1R8 KO.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.009">http://dx.doi.org/10.7554/eLife.21735.009</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21735-fig6-v1"/></fig></p></sec><sec id="s2-5"><title>The transcriptional regulator MeCP2 mediates the alterations in spine morphogenesis, synaptic transmission and synaptic plasticity observed in IL-1R8 KO hippocampal neurons</title><p>It is known that mTOR is at the cross road of plasticity, memory and disease processes (<xref ref-type="bibr" rid="bib38">Hoeffer and Klann, 2010</xref>). Reduced AKT/mTOR signaling and protein synthesis dysregulation has been described in the brain of the MeCP2 KO Rett syndrome animal model, thus indicating that MeCP2 is an upstream regulator of the Akt/mTOR pathway (<xref ref-type="bibr" rid="bib71">Ricciardi et al., 2011</xref>). Western blotting and immunofluorescence analysis of MeCP2 in IL-1R8 KO hippocampal cultures revealed higher levels of the protein with respect to controls (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>), in the absence of differences in the transcript levels (normalized counts WT = 4857 ± 97.46, WT+IL1β = 4936 ± 281.3, IL-1R8 KO = 4864 ± 201.7, IL-1R8 KO+Anakinra = 3599 ± 232.6, mean ± SEM, p&gt;0,05, one-way ANOVA, Tukey’s multiple comparisons test). However, relative to previous reports (<xref ref-type="bibr" rid="bib71">Ricciardi et al., 2011</xref>), we found that IL-1R activation and mTOR pathway can be also an upstream regulator of MeCP2. Indeed, overnight treatment of IL-1R8 KO neurons with either IL1Ra (20 or 100 ng/ml) or rapamycin (20 nM) resulted in the normalization of MeCP2 levels, as assessed by Western Blotting (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>) or immunofluorescence (<xref ref-type="fig" rid="fig7">Figure 7C and D</xref>), thus indicating that MeCP2 is increased in IL-1R8 KO neurons as a consequence of the hyperactivation of IL-1R and downstream to the mTOR pathway. Finally MeCP2 levels were increased by immunofluorescence (<xref ref-type="fig" rid="fig7">Figure 7E and F</xref>) and by western blotting (<xref ref-type="fig" rid="fig7">Figure 7G and H</xref>) also in cultured WT neurons exposed to IL-1β (40 ng/ml for 14 hr). As a further support to this view, a reduction of MeCP2 intensity was detected in WT neurons exposed to either IL-1Ra or rapamycin and examined by immunofluorescence (<xref ref-type="fig" rid="fig7">Figure 7C and D</xref>). Consistently, MeCP2 levels, analyzed by Western Blotting, were significantly lower in both hippocampus and cortex of adult IL-1R KO mice (7 months old) (normalized integrated density of MeCP2 levels in hippocampus, WT: 1 ± 0,0535 (n = 5); IL-1R KO: 0795 ± 0,0121 (n = 5), Student t test, p&lt;0,01. Normalized integrated density of MeCP2 levels in cortex, WT: 1 ± 0,0586 (n = 5); IL-1R KO: 0,7792 ± 0,0473 (n = 5), Student t test, p&lt;0005).<fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.21735.010</object-id><label>Figure 7.</label><caption><title>IL-1R8 KO neurons display higher MeCP2 levels that are responsible for LTP defects in IL-1R8 KO neurons.</title><p>(<bold>A</bold>) MeCP2 expression analyzed by western blotting in cultured neurons from WT or IL-1R8 KO neurons treated or not with IL-1Ra (20 ng/ml), IL-1Ra (100 ng/ml) or Rapa (20 nM). A higher MeCP2 expression is detectable in IL-1R8 KO neurons, which is reduced by IL-1Ra or Rapa. (<bold>B</bold>) Quantitative analysis of MeCP2 expression. Number of replicates: 3 (WT), 3 (IL-1R8 KO), 3 (IL-1R8 KO, IL1Ra 20), 3 (IL-1R8 KO, IL1Ra 100), 3 (IL-1R8 KO, Rapa); one-way ANOVA analysis of variance followed by post hoc Tukey test. (<bold>C</bold>) MeCP2 and MAP2 immunocytochemical staining of 16 DIV hippocampal WT or IL-1R8 KO neurons treated overnight (14 hr) with vehicle, IL1Ra (20 ng/ml) or Rapa (20 nM). Scale bar, 40 μm (low magnification image), 20 μm (insert). (<bold>D</bold>) Quantitative analysis of MeCP2 immunoreactivity in neurons treated as above. Number of analyzed neurons: 88 (WT), 60 (WT, IL1Ra), 55 (WT, Rapa), 52 (IL-1R8 KO), 66 (IL-1R8 KO, IL1Ra), 81 (IL-1R8 KO, Rapa); one-way ANOVA analysis of variance followed by post hoc Tukey test. (<bold>E</bold>) Immunocytochemical staining for MeCP2 and β3-tubulin of 16 DIV WT hippocampal neurons, exposed or not to IL1β (40 ng/ml) overnight. Scale bar, 40 μm. (<bold>F</bold>) Quantitative analysis of MeCP2 immunoreactivity reveals higher MeCP2 levels in IL1β treated neurons. Number of analyzed neurons: 288 (WT), 227 (WT, IL1β); Student t test. (<bold>G</bold> and <bold>H</bold>) Representative western blotting (<bold>G</bold>) and quantitative analysis (<bold>H</bold>) of MeCP2 expression in WT neurons treated with IL-1β (40 ng/ml). Number of replicates, WT: n = 5; WT + IL1β 40: n = 5 independent experiments. Mann Whitney test. * indicates significance compared to WT, # indicates significance compared to IL-1R8 KO.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.010">http://dx.doi.org/10.7554/eLife.21735.010</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21735-fig7-v1"/></fig></p><p>MeCP2, a synaptic factor that controls spine morphogenesis and plasticity (<xref ref-type="bibr" rid="bib13">Chao et al., 2007</xref>; <xref ref-type="bibr" rid="bib62">Nelson et al., 2006</xref>; <xref ref-type="bibr" rid="bib93">Zoghbi, 2003</xref>; <xref ref-type="bibr" rid="bib3">Asaka et al., 2006</xref>; <xref ref-type="bibr" rid="bib35">Guy et al., 2007</xref>; <xref ref-type="bibr" rid="bib57">Moretti et al., 2006</xref>), needs to be tightly regulated in the human brain. Indeed, besides the well-known pathological traits - intellectual disability and delayed development - caused by MeCP2 duplication (<xref ref-type="bibr" rid="bib69">Ramocki et al., 2010</xref>) or MeCP2 loss of function (<xref ref-type="bibr" rid="bib12">Chahrour and Zoghbi, 2007</xref>), even mild differences in MeCP2 expression turned out to profoundly impact human behavior and brain function (<xref ref-type="bibr" rid="bib79">Tantra et al., 2014</xref>). To investigate whether the morphological and functional defects observed in the IL-1R8 KO neurons could directly result from increased MeCP2 levels, we silenced MeCP2 in neuronal cultures from IL-1R8 KO mice through the use of a well characterized shRNA construct (Sh MeCP, kind gift of Dr. M. Greenberg, Harvard Medical School), which has been widely used in literature to reduce MeCP2 expression (<xref ref-type="bibr" rid="bib91">Zhou et al., 2006</xref>; <xref ref-type="bibr" rid="bib8">Blackman et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Gangisetty et al., 2014</xref>; <xref ref-type="bibr" rid="bib46">Kishi et al., 2016</xref>; <xref ref-type="bibr" rid="bib7">Bedogni et al., 2016</xref>). DIV 12 neurons were transfected with shCTRL or shMeCP2, and examined for their ability to undergo LTP four days later. We first quantitated the extent of MeCP2 reduction in treated cultures and found that the use of shRNA construct allowed to achieve a protein reduction ranging from 59% to 67%. However, given the higher MeCP2 expression in IL-1R8 KO neurons, the levels of MeCP2 in shRNA–treated IL-1R8 KO neurons ended up to be comparable to those in untreated WT neurons (<xref ref-type="fig" rid="fig8">Figure 8A and B</xref>). While WT neurons with silenced MeCP2 showed abnormal spine morphology, with a decreased density of mushroom spines (<xref ref-type="fig" rid="fig8">Figure 8C and D</xref>) and PSD95 puncta (<xref ref-type="fig" rid="fig8">Figure 8C and E</xref>), IL-1R8 KO neurons with silenced MeCP2 reverted the morphological phenotype. Even more interestingly, MeCP2 silenced neurons rescued their ability to undergo LTP (<xref ref-type="fig" rid="fig8">Figure 8F–H</xref>). Therefore, recovery of MeCP2 to control levels is sufficient to acutely rescue the synaptic defects observed in IL-1R8 KO neurons.<fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.21735.011</object-id><label>Figure 8.</label><caption><title>Higher MeCP2 levels are responsible for LTP defects in IL-1R8 KO neurons.</title><p>(<bold>A</bold>) MeCP2 and MAP2 immunocytochemical staining and (<bold>B</bold>) quantitative analysis of MeCP2 immunoreactivity in 16 DIV WT and IL-1R8 KO neurons transfected with SH CTRL or SH MeCP2. Scale bar 40 μm. Number of analyzed neurons: 23 (WT, SH CTRL), 28 (WT, SH MeCP2), 46 (IL-1R8 KO, SH CTRL), 40 (IL-1R8 KO, SH MeCP2); one-way ANOVA analysis of variance followed by post hoc Tukey test. * indicates significance compared to WT + SH CTRL, # indicates significance compared to IL-1R8 KO + SH CTRL. (<bold>C</bold>) PSD-95 immunocytochemical staining of SH CTRL- or SH MeCP2-transfected, DIV 16 hippocampal cultures from WT or IL-1R8 KO mice. Neurons were transfected at DIV 12 and the LTP protocol was applied at DIV 16. Scale bar, 5 μm. (<bold>D</bold>) Quantitative analysis of mushroom spine density in WT and IL-1R8 KO neurons treated as above. Number of analyzed neurons: 30 (WT, SH CTRL, no LTP), 29 (WT, SH CTRL, + LTP), 30 (WT, SH MeCP2, no LTP), 29 (WT, SH MeCP2, + LTP), 59 (IL-1R8 KO, SH CTRL, no LPT), 60 (IL-1R8 KO, SH CTRL, + LTP), 54 (IL-1R8 KO, SH MeCP2, no LTP), 58 (IL-1R8 KO, SH MeCP2, + LTP); one-way ANOVA analysis of variance followed by post hoc Tukey test. (<bold>E</bold>) Quantitative analysis of PSD-95 density. Number of analyzed neurons: 17 (WT, SH CTRL, no LTP), 15 (WT, SH CTRL, + LTP), 16 (WT, SH MeCP2, no LTP), 15 (WT, SH MeCP2, + LTP), 15 (IL-1R8 KO, SH CTRL, no LTP), 15 (IL-1R8 KO, SH CTRL, + LTP), 15 (IL-1R8 KO, SH MeCP2, no LTP), 17 (IL-1R8 KO, SH MeCP2, + LTP); one-way ANOVA analysis of variance followed by post hoc Tukey test. Data indicate that reduction of MeCP2 expression restores synaptic potentiation. (<bold>F</bold>) Representative traces of mEPSC recorded from IL-1R8 KO neurons transfected with SH CTRL or SHMeCP2 before and after LTP induction. (<bold>G</bold> and <bold>H</bold>) Quantitation of mEPSC frequency and amplitude of neurons treated as above. Analysis of normalized mEPSC frequency and amplitude reveals that only neurons transfected with SH MeCP2 undergo LTP. Number of recorded neurons: 14 (IL-1R8 KO, SH CTRL, no LTP), 7 (IL-1R8 KO, SH CTRL, + LTP), 19 (IL-1R8 KO, SH MeCP2, no LTP), 7 (IL-1R8 KO, SH MeCP2, + LTP). Mann Whitney test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.011">http://dx.doi.org/10.7554/eLife.21735.011</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21735-fig8-v1"/></fig></p></sec><sec id="s2-6"><title>Increased MeCP2 levels are detectable in the cortex and hippocampus of IL-1R8 deficient mice</title><p>The increased MeCP2 expression detected in primary IL-1R8 KO neurons was also confirmed in vivo. Immunohistochemical analysis of hippocampus (CA1 region) and cortex revealed a significantly higher expression of MeCP2 in IL-1R8 KO neurons compared to WT, as indicated by the quantitation of the MeCP2 integrated density value per neuron and the cumulative distribution of neuronal integrated density values (<xref ref-type="fig" rid="fig9">Figure 9A–E</xref>). Consistently, western blot analysis of either hippocampus or cortex revealed higher levels of MeCP2 in the brains of IL-1R8 KO mice (<xref ref-type="fig" rid="fig9">Figure 9F–H</xref>). Notably, administration of 30 mg/kg Anakinra to IL-1R8 KO mice for three consecutive days significantly reduced MeCP2 protein (<xref ref-type="fig" rid="fig9">Figure 9F–H</xref>). These data indicate that higher levels of MeCP2 are detectable in the brain of IL-1R8 KO mice and that the acute inhibition of IL-1R by Anakinra reduces hippocampal and cortical MeCP2 levels.<fig id="fig9" position="float"><object-id pub-id-type="doi">10.7554/eLife.21735.012</object-id><label>Figure 9.</label><caption><title>Higher MeCP2 levels in the brain of IL-1R8 KO mice.</title><p>(<bold>A</bold>) Representative images of brain sections (CA1 hippocampus, upper panels and cortex, lower panels) of WT and IL-1R8 KO mice (1 month old) stained for MeCP2 and NeuN, as indicated. (<bold>B-E</bold>) Graphs show quantitation of MeCP2 mean integrated density values and the cumulative distributions of neuronal MeCP2 integrated density values in CA1 hippocampal neurons (<bold>B</bold> and <bold>C</bold>) and cortical neurons (<bold>D</bold> and <bold>E</bold>). Number of analyzed mice and neurons: WT: n = 3 mice, hippocampal neurons = 572, cortical neurons = 481. IL-1R8 KO: n = 3 mice, hippocampal neurons = 559, cortical neurons = 471. Statistical comparison: Mann-Whitney Test for <bold>B</bold> and <bold>D</bold>; KolmogorovSmirnov Comparison (<ext-link ext-link-type="uri" xlink:href="http://www.physics.csbsju.edu/stats/KS-test.html">http://www.physics.csbsju.edu/stats/KS-test.html</ext-link>), D values are: 0,2084 with a corresponding p&lt;0.0001 (panel <bold>C</bold>) and 0,1396 with a corresponding p=0.0005 (panel <bold>E</bold>). (<bold>F-H</bold>) Western blotting (<bold>F</bold>) and quantitative analysis (<bold>G and H</bold>) of MeCP2 expression in cortices and hippocampi of 3 months old WT and IL-1R8 KO mice or in IL-1R8 KO mice treated with Anakinra (30 mg/kg) for 3 days. Number of analyzed mice: 6 WT, 5 IL-1R8 KO and 5 IL-1R8 KO + Anakinra (<bold>G</bold>); 6 WT, 6 IL-1R8 KO and 4 IL-1R8 KO + Anakinra (<bold>H</bold>). Statistical test: one-way ANOVA analysis of variance followed by post hoc Tukey test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.012">http://dx.doi.org/10.7554/eLife.21735.012</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21735-fig9-v1"/></fig></p></sec><sec id="s2-7"><title>Inhibition of IL-1β receptor by Anakinra rescues behavioral defects</title><p>We finally investigated whether behavioral deficits consequent to the genetic lack of IL-1R8 could be rescued in the adult mice by the pharmacological inhibition of IL-1R. To this aim IL-1R8 KO mice were analyzed for novel place recognition test three days after the treatment with the anti-inflammatory compound glycyrrhizic acid (50 mg/kg), which binds to high-mobility group box 1 (HMGB1) protein and inhibits IL-1 activity (<xref ref-type="bibr" rid="bib74">Sakamoto et al., 2001</xref>; <xref ref-type="bibr" rid="bib56">Mollica et al., 2007</xref>) or with 30 mg/kg Anakinra. Both treatments ameliorated the spatial memory impairment of IL-1R8 KO mice (<xref ref-type="fig" rid="fig10">Figure 10A</xref>), with 50% IL-1R8 KO mice displaying a significantly improved discrimination index after Anakinra treatment (p=0,0168 paired Student’s t-test). IL-1R8 KO mice were also tested for the Morris water maze and the rewarded T maze. In line with the concept that alternation, either rewarded or spontaneous, detects hippocampal dysfunction even better than the Morris water maze (reviewed in <xref ref-type="bibr" rid="bib20">Deacon and Rawlins, 2006</xref>), the rewarded T-maze (<xref ref-type="fig" rid="fig10">Figure 10C</xref>), but not the Morris water maze (<xref ref-type="fig" rid="fig10">Figure 10B</xref>), revealed an impairment of spatial memory in IL-1R8 KO mice. Treatment with Anakinra ameliorated the performance (<xref ref-type="fig" rid="fig10">Figure 10C</xref>). Consistent with these data, IL-1R8 KO mice performed a significantly higher number of errors during the acquisition phase with respect to WT and Anakinra-treated IL-1R8 KO mice (<xref ref-type="fig" rid="fig10">Figure 10D</xref>). Interestingly, also WT mice treated with Anakinra displayed impaired spatial memory (<xref ref-type="fig" rid="fig10">Figure 10C</xref>). The lack of increased number of errors in WT mice treated with Anakinra (<xref ref-type="fig" rid="fig10">Figure 10D</xref>) is possibly attributable to the enhancement of freezing behavior. These data indicate that Anakinra ameliorates the spatial memory of IL-1R8 KO mice and confirm that blockade of IL-1R originates learning defects in WT mice.<fig id="fig10" position="float"><object-id pub-id-type="doi">10.7554/eLife.21735.013</object-id><label>Figure 10.</label><caption><title>Anakinra rescues behavioral defects in IL-1R8 KO mice.</title><p>(<bold>A</bold>) Analysis of novel-place object recognition task in WT and IL-1R8 KO mice shows a defect in spatial learning in IL-1R8 KO mice (one-way ANOVA followed by Bonferroni multiple comparison test). 3 days i.p. treatment with 50 mg/kg glycyrrhizic acid or 30 mg/kg Anakinra ameliorates IL-1R8 KO mice performance. Number of analyzed mice: 15 (WT), 6 (WT+Anakinra), 18 (IL1-R8 KO), 3 (IL1-R8 KO+glycyrrhizic acid) and 10 (IL1-R8 KO+Anakinra). (<bold>B</bold>) IL-1R8 deficiency or treatment with Anakinra did not affect the learning performance in the Water Maze navigation task. Number of analyzed mice: 5 (WT), 5 (WT+Anakinra), 5 (IL1-R8 KO), and 5 (IL1-R8 KO+Anakinra). (<bold>C</bold>) IL1-R8 KO mice displayed impaired spatial memory in the rewarded T-maze task, as indicated by the low percentage of animals reaching the criterion. Treatment with Anakinra ameliorated the performance of IL1-R8 KO mice, while worsening the learning ability of WT. Number of analyzed mice: 5 (WT), 3 (WT+Anakinra), 6 (IL1-R8 KO) and 5 (IL1-R8 KO+Anakinra). (<bold>D</bold>) IL1-R8 KO mice showed a significant increase in the total number of errors during the acquisition phase as compared to the WT, which was significantly reduced by treatment with Anakinra. One-way ANOVA followed by Tukey’s multiple comparison test. Number of analyzed mice: 6 (WT), 5 (WT+Anakinra), 5 (IL1-R8 KO) and 5 (IL1-R8 KO+Anakinra). All the mice were 3–6 months old.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.013">http://dx.doi.org/10.7554/eLife.21735.013</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21735-fig10-v1"/></fig></p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Finely tuned expression of immune molecules has been found to modulate CNS function (<xref ref-type="bibr" rid="bib21">Deverman and Patterson, 2009</xref>), both throughout normal development and in pathological conditions. During development, immune molecules such as CXCR4, interferon γ, IL-1β, IL-6, IL-9, IL-10 and transforming growth factor β affect neurogenesis, neuronal migration, axon guidance, synapse formation, activity-dependent refinement of circuits and synaptic plasticity (<xref ref-type="bibr" rid="bib21">Deverman and Patterson, 2009</xref>; <xref ref-type="bibr" rid="bib90">Zhao and Schwartz, 1998</xref>). In line with this concept, mice genetically devoid of IL-1R8, a receptor which dampens the activation of the TLRs and IL-1R signalling pathways, are neurologically impaired, showing defects in novel place recognition task, spatial reference memory and LTP, defects that occur in the absence of any external inflammatory stimuli (<xref ref-type="bibr" rid="bib18">Costello et al., 2011</xref>). However, the molecular processes at the basis of these defects are still elusive.</p><p>Our study provides two major breakthroughs in the field of the cross talk between nervous and immune systems: first, it demonstrates that hyperactivation of the IL1R pathway results in the overexpression of MeCP2, a synaptic factor that controls spine morphogenesis, synaptic transmission and plasticity, which is responsible for syndromes associated with intellectual disability such as Rett syndrome and MeCP2 duplication syndrome; second it provides the proof-of-concept that the synaptic and behavioral defects consequent to genetic hyperactivation of the IL-1R pathway can be rescued in the adult by pharmacological treatment with IL-1Ra. Of note, the acute application of IL-1β to mature neurons recapitulates similar synaptic defects and alterations of MeCP2 expression. Consistently, transcriptomic analysis of cortices from WT mice (treated or not with IL-1β) and from IL-1R8 KO animals (treated or not treated with Anakinra) show that a common set of genes is transcriptionally altered in WT mice treated with IL-1β and in IL-1R8 KO animals, including genes controlling synaptic function and spine morphogenesis. The expression of this set of genes is restored to normal levels by treatment with Anakinra in IL-1R8 KO mice. These findings have important repercussions in the clinic, as they could open the road to the use of anti-inflammatory drugs as therapeutic treatments for neuropsychiatric illnesses such as schizophrenia, autism and mental retardation, for all of which an immune component has been demonstrated (<xref ref-type="bibr" rid="bib44">Khandaker et al., 2015</xref>; <xref ref-type="bibr" rid="bib80">Theoharides et al., 2015</xref>; <xref ref-type="bibr" rid="bib88">Young et al., 2016</xref>).</p><p>Our study identifies the crucial involvement of the AKT/mTOR pathway in IL-1R8 KO neurons (<xref ref-type="fig" rid="fig10">Figure 10H</xref>). IL-1R8 has been previously reported to regulate mTOR kinase activity in Th17 cells, playing a nonredundant role in controlling mTOR-dependent differentiation, proliferation and cytokine production (<xref ref-type="bibr" rid="bib34">Gulen et al., 2010</xref>). The demonstration that the PI3K/Akt/mTOR pathway is at the root of synaptic defects in IL-1R8 KO neurons is in line with the established involvement of this pathway in dendritic tree development and spine formation in neurons (<xref ref-type="bibr" rid="bib76">Sarbassov et al., 2006</xref>), as well as actin cytoskeleton dynamics and synaptic plasticity (<xref ref-type="bibr" rid="bib41">Jaworski and Sheng, 2006</xref>). Remarkably, the mTOR pathway is closely linked to ILR/TLR signaling since PI3 kinase is required for activation of NF-κB by IL-1 (<xref ref-type="bibr" rid="bib34">Gulen et al., 2010</xref>). Furthermore, the signaling module containing the MyD88 adaptor protein, together with phosphorylated IRAK and TRAF6, which is downstream to both IL-1R and TLRs activation, is essential for PI3K recruitment and Akt activation, making mTOR one of the downstream targets of ILR/TLRs signaling (<xref ref-type="bibr" rid="bib34">Gulen et al., 2010</xref>). Consistent with the involvement of mTOR in the IL-1R8 KO neuron defects, treatment with the PI3 kinase inhibitors, LY294002 and wortmannin restored the neuronal ability to sustain LTP. Moreover, specific inhibition of mTOR by the drug rapamycin rescues synaptic morphology in IL-1R8 KO neurons. These results indicate that the PI3K-regulated pathway is involved in the downstream signaling that connects excessive IL-1R activation to the morphological and functional impairments of dendritic spines observed in IL-1R8 KO neurons.</p><p>More importantly, our study shows for the first time that activation of IL-1R in neurons increases the levels of MeCP2, both in vitro and in vivo. Fine-tuning of MeCP2 expression is required for proper synapse function (reviewed in <xref ref-type="bibr" rid="bib60">Na et al. [2013]</xref>). Indeed, lack of expression of MeCP2 results in deceleration of body and head growth rate, problems in motor and speech capabilities, irregularities in motor activity and difficulties in breathing, and also in cognitive defects characteristic of an autism-spectrum disorder (reviewed in <xref ref-type="bibr" rid="bib65">Percy and Lane [2005]</xref>). Mouse models of MeCP2 duplication display a neurological phenotype, stereotyped and repetitive movements, epilepsy, spasticity, hypoactivity, early death (<xref ref-type="bibr" rid="bib15">Collins et al., 2004</xref>) and defects in dendritic arborization and spine morphology (<xref ref-type="bibr" rid="bib42">Jiang et al., 2013</xref>). In humans, sporadic mutations in the gene coding for MeCP2 results in Rett syndrome (<xref ref-type="bibr" rid="bib1">Amir et al., 1999</xref>), while a double dosage of MeCP2 causes a severe developmental delay and mental retardation (<xref ref-type="bibr" rid="bib53">Lubs et al., 1999</xref>). Thus, MeCP2 levels must be finely tuned as even mild over-expression of this factor can have a robust effect. We first demonstrate here that immune activation controls the expression of MeCP2 in neurons. The possibility that MeCP2 phosphorylation, by which MeCP2 also modulates gene expression levels, is altered in these models is an open issue. MeCP2 can act as a transcriptional activator (when interacting with CREB) but primarily functions as a transcriptional repressor associated with mSin3A and HDACs repressor complexes (<xref ref-type="bibr" rid="bib11">Chahrour et al., 2008</xref>; <xref ref-type="bibr" rid="bib43">Jones et al., 1998</xref>; <xref ref-type="bibr" rid="bib61">Nan et al., 1998</xref>). Consistently, we observed a prevalence of downregulation over upregulation in the expression of the deregulated genes in WT mice treated with IL-1β and in IL-1R8 KO animals, suggesting that the repressor function of MeCP2 might dominate in response to IL-1R activity. Indeed, gene ontology enrichment analysis for the deregulated genes highlighted negative regulation of transcription from RNA polymerase II promoter and negative regulation of gene expression among the most affected biological processes in IL-1R8 KO animals (<xref ref-type="supplementary-material" rid="SD4-data">Supplementary file 4</xref>).</p><p>The regulation of MeCP2 protein levels by IL-1R8 appears to result from enhanced activity of IL-1R. IL-1β is a fundamental factor of inflammatory responses in the brain. It is expressed at baseline levels in the healthy brain, and its expression increases following peripheral infection, surgery, or brain injury, as well as in neurodegenerative diseases (<xref ref-type="bibr" rid="bib73">Rothwell and Luheshi, 2000</xref>). Increases in IL-1β levels lead to cognitive decline, in particular in hippocampal-dependent tasks (<xref ref-type="bibr" rid="bib68">Rachal Pugh et al., 2001</xref>). IL-1β overexpression for two weeks in an inducible transgenic mouse was found to cause impairment in long-term contextual and spatial memory, without effects on short-term and non-hippocampal memory (<xref ref-type="bibr" rid="bib37">Hein et al., 2010</xref>). An increase in IL-1β levels due to Escherichia coli infection leads to defects in contextual fear conditioning, with loss of memory prevented by IL1Ra (<xref ref-type="bibr" rid="bib5">Barrientos et al., 2009</xref>; <xref ref-type="bibr" rid="bib24">Frank et al., 2010</xref>). Remarkably, we show that neuron treatment with IL-1β not only leads to an increase in immature spines unable to undergo LTP, but also augments MeCP2 levels. In this context, as with E. coli infection, IL1Ra/Anakinra restores synaptic function.</p><p>Our demonstration that enhanced IL-1R activity, due to either lack of IL-1R8 or excessive IL-1β signaling, impacts synapse function through regulating the expression of MeCP2 expands in a critical way previous research on the role of MeCP2 in cognition (<xref ref-type="bibr" rid="bib60">Na et al., 2013</xref>): we show here that MeCP2 is a fundamental node linking inflammation with synaptic damage and we demonstrate that inhibition of IL-1R pathway by IL-1Ra restores synaptic structure and function in vitro. We also demonstrate that the acute treatment with Anakinra, a pharmacological agent currently in use to treat chronic inflammation, restores synaptic plasticity in vivo. Although we do not have the proof that this occurs exclusively through MeCP2 reduction, our data indicate that immune drugs may be efficacious for treating neurological deficits associated with immune pathologies with a genetic basis and justify further research into anti-inflammatory treatment for selected brain pathologies. Indeed, recurrent infections have been found to occur in 70% of individuals affected by MeCP2 duplication syndrome, which lead to further deterioration of the general and neurological status, being even fatal in some patients (<xref ref-type="bibr" rid="bib82">van Esch et al., 2012</xref>). Also, in patients affected by cryopyrin-associated periodic syndrome (CAPS), a group of rare autoinflammatory diseases with genetic basis, the levels of IL-1β are fivefold higher than in healthy individuals, leading to persistent unregulated systemic inflammation (<xref ref-type="bibr" rid="bib40">Janssen et al., 2004</xref>; <xref ref-type="bibr" rid="bib47">Lachmann et al., 2009</xref>). CAPS is characterized by recurrent bouts of fever with malaise and chills, urticarial neutrophilic, eye redness due to conjunctivitis, arthralgia and myalgia with intense fatigue. Children affected by CAPS are believed to show symptoms of intellectual disability. Mental and hearing defects are reversed following treatment with Anakinra (<xref ref-type="bibr" rid="bib31">Goldbach-Mansky, 2011</xref>; <xref ref-type="bibr" rid="bib30">Goldbach-Mansky et al., 2006</xref>; <xref ref-type="bibr" rid="bib50">Lepore et al., 2010</xref>; <xref ref-type="bibr" rid="bib55">Miyamae et al., 2010</xref>; <xref ref-type="bibr" rid="bib63">Neven et al., 2010</xref>) and with specific neutralization of IL-1β with canakinumab. Our study opens the possibility that further cognitive deterioration may result from the enhanced inflammation and hyperactivation of the IL-1 signaling pathway, which might further increase MeCP2 levels in a harmful positive feedback loop. The challenging possibility that treatment with Anakinra may help interrupting this spiral and ameliorating the cognitive deficits in affected individuals is worth to be tested.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Animals</title><p>IL-1R8 KO mice (<xref ref-type="bibr" rid="bib28">Garlanda et al., 2004</xref>) and double IL-1R8 KO IL-1R KO mice (<xref ref-type="bibr" rid="bib84">Véliz Rodriguez et al., 2012</xref>) were obtained from Istituto Clinico Humanitas IRCCS, Milan, Italy. Primary hippocampal cultures were performed from E17 embryos. Tissues for WB analysis were taken from 3-month-old male animals. All the experimental procedures followed the guidelines established by the European Legislation (Directive 2010/63/EU), and the Italian Legislation (L.D. no 26/2014).</p></sec><sec id="s4-2"><title>Golgi staining and quantification of dendritic spines</title><p>Mice (3 months old) were deeply anesthetized with chloral hydrate (4%; 1 ml/100 g body weight, i.p.) and perfused intracardially with 0.9% saline solution. The brains were removed and stained by modified Golgi-Cox method as described in (<xref ref-type="bibr" rid="bib54">Menna et al., 2013</xref>) with slight modifications. Coronal sections of 100 µm thickness from the dorsal hippocampus were obtained using a vibratome (VT1000S, Leica, Wetzlar, Germany). These sections were collected free floating in 6% sucrose solution and processed with ammonium hydroxide for 15 min, followed by 15 min in Kodak Film Fixer, and finally were rinsed with distilled water, placed on coverslips, dehydrated and mounted with a xylene-based medium. Spine density was counted on the secondary branches of apical dendrites of pyramidal neurons located in the CA1 subfield of the dorsal hippocampus. At least 30 neurons per animal were evaluated.</p></sec><sec id="s4-3"><title>Immunofluorescent staining on free-floating sections</title><p>Mice (1 month old) were deeply anesthetized with chloral hydrate (4%; 1 ml/100 g body weight, i.p.) and perfused intracardially with 4% paraformaldehyde. Immunofluorescent staining was carried out on free-floating sections as described in (<xref ref-type="bibr" rid="bib54">Menna et al., 2013</xref>). Free-floating sections at the level of dorsal hippocampus were processed with the specific antibodies as indicated, followed by incubation with the secondary antibodies, counterstained with DAPI and mounted in Fluorsave (Calbiochem, San Diego, CA, USA).</p><p>Primary antibodies: anti-vGLUT-1 (guinea pig polyclonal antibody, 1:1000; No. 135 304 Synaptic System), anti-MeCP2 (rabbit polyclonal, 1:200; M9317 Sigma), anti-NeuN (mouse monoclonal, 1:500; MAB377 Millipore). Sections were examined by means of a Zeiss LSM 510 META confocal microscope (Leica Microsystems, Germany). Images were acquired in the stratum pyramidale or stratum radiatum of the CA1 subfield of the hippocampus (as indicated) using the x40 oil immersion lens with an additional electronic zoom factor of up to 3 (voxel sizes of 0.10 × 0.10×1 μm) maintaining the parameters of acquisition (laser power, pinhole, gain, offset) constant among groups.</p></sec><sec id="s4-4"><title>Behavior</title><sec id="s4-4-1"><title>Novel place object recognition</title><p>This test was used to assess whether mice were able to recognize that an object that they had experienced before had changed location in the arena, as previously described (<xref ref-type="bibr" rid="bib17">Corradini et al., 2012</xref>). The test was conducted in an open plastic arena (60x x50x x30 cm) in two phases. During the first phase, lasting two days, mice were habituated to the test arena for 10 min on the first day. On the second day, mice were subjected to familiarization (T1) and novel place recognition (T2). During familiarization, two identical objects were placed in the North and South corners of the arena. Each animal was placed in the center of the arena, equidistant from the objects, and was left for a maximum of 10 min or until it had completed 30 s of cumulative object exploration, then it was returned to its home cage. 120 min later the mouse was introduced in the same arena with one object relocated to the East instead of the South corner for a maximum of 5 min. Scoring was performed in the same manner as during familiarization.</p><p>To assess the role of inflammation in the cognitive performances observed in IL-1R8 KO mice, 30 days later mice were treated with 50 mg/kg i.p. glycyrrhizin acid, 30 mg/kg, i.p. Anakinra or vehicle for 3 days and were re-subjected to the T2.</p><p>The objects used consisted of plastic cylinders and colored plastic stacks. The arena and the objects were cleaned with 70% ethanol after each trial. A discrimination index was calculated to evaluate the performance of each mouse as (N-F)/(N+F), where N = time spent exploring the object in the new location during T2, and F = time spent exploring the object in the familiar location during T2. Mice who did not move in the arena were excluded from the analysis.</p></sec><sec id="s4-4-2"><title>Water maze place navigation</title><p>Spatial memory was assessed in a Morris water maze as previously reported (<xref ref-type="bibr" rid="bib17">Corradini et al, 2012</xref>) with slight modification. Briefly, training and testing of mice were done under 12 lux diffuse light in a circular pool arena made of white polypropylene (diameter 100 cm, wall height 60 cm), filled with water (made opaque by the addition of milk) to a height of 30 cm and maintained at 24–26°C. A 10 cm diameter target platform of transparent polypropylene was placed 0.5 cm below the water surface in the N, S, E, or W quadrant at 20 cm from the wall. Each mouse was released to the pool from different starting points and was trained for a constant platform position over two days with five trials per day separated by 30–60 min intervals and each trial lasting maximally 120 s. The latency to find the escape platform was measured.</p></sec><sec id="s4-4-3"><title>T-maze</title><p>The T-maze was constructed of gray plexiglass, with stem length of 40 cm and arm length of 90 cm; each section was 11 cm wide with 19 cm high side walls. Animals were first food-deprived until reaching the 85% to 90% of their free-feeding body weight, and they were habituated to obtain food from cups placed at the ends of the arms of the T-maze for 5 days, with one acclimation per day (<xref ref-type="bibr" rid="bib58">Moy et al., 2008</xref>). For each mouse, one arm was designated as the correct arm and a reinforcer (Kellogg’s cereal) was available in the cup at the end of the arm each trial. The correct arm was on the right side for half of the mice, and on the left side for the other half, for each genotype. Each mouse was placed at the maze start and was given a free choice to enter either arm. Latency to enter an arm, number of errors in arm selection, and number of days to reach the criterion – that is, showing 70% of correct choices for three consecutive days - were recorded by a human observer. To assess the role of IL-1R pathway in the cognitive performances observed in IL-1R8 KO mice, an experimental group was treated with daily i.p. injection of 30 mg/kg Anakinra for the whole duration of the experiment. Animals showing freezing behavior, who did not move in the maze, were excluded from the analysis.</p></sec></sec><sec id="s4-5"><title>In vitro experiments</title><sec id="s4-5-1"><title>Cell cultures</title><p>Mouse hippocampal neurons were established from the hippocampi of embryonic stage E17 fetal mice (<xref ref-type="bibr" rid="bib83">Verderio et al., 1994</xref>). The dissociated cells were plated onto glass coverslips coated with poly-L-lysine at densities of 95 cells/mm2. The cells were maintained in Neurobasal (Invitrogen, San Diego, CA) with B27 supplement and antibiotics, 2 mM glutamine, and glutamate (neuronal medium).</p></sec><sec id="s4-5-2"><title>Acute downregulation of MeCP2 expression</title><p>Silencing of MeCP2 was achieved via transfection of Sh CTRL and Sh MeCP2. Constructs are a kind gift of Michael Greenberg and were obtained as described in (<xref ref-type="bibr" rid="bib91">Zhou et al., 2006</xref>).</p></sec><sec id="s4-5-3"><title>Transfection</title><p>Mouse hippocampal neurons were transfected with different plasmids using Lipofectamine 2000 (Invitrogen) at DIV12. Cultures were fixed and stained at DIV 16.</p></sec><sec id="s4-5-4"><title>Immunocytochemical staining and image analysis</title><p>Immunofluorescence staining was carried out as described in (<xref ref-type="bibr" rid="bib83">Verderio et al., 1994</xref>) using the following antibodies: PSD-95 (1:400; monoclonal; UC Davis/NIH NeuroMab Facility, CA), MeCP2 (1:200; polyclonal; Cell Signaling), MAP2 (1:300; monoclonal; Immunological Sciences). Images were acquired using a Leica SPE confocal microscope. Images of primary hippocampal cultures were acquired with a Leica SPE confocal X 63 oil immersion lens (1,024 × 1,024 pixels). Each image consisted of a stack of images taken through the z-plane of the cell. Confocal microscope settings were kept the same for all scans in each experiment.</p></sec><sec id="s4-5-5"><title>Dendritic spines analysis</title><p>For the analysis of spine density and size the program NeuronStudio was utilized. On the basis of morphology, the spines were classified into the following categories: (1) Thin: spines with a long neck and a visible small head; (2) Mushroom: big spines with a well-defined neck and a very voluminous head. PSD-95 puncta mean size was evaluated with Imaris, in particular with the Spots function. PSD-95 density analysis was performed using ImageJ software (NIH, Bethesda, Maryland, USA). At least four dendritic branches were analyzed for each neuron. The number of analyzed neurons is reported in each figure legend. At least three independent replications were performed for each experimental setting. Control data refer to each single experimental session.</p></sec></sec><sec id="s4-6"><title>Cell culture electrophysiology</title><p>Whole cell voltage-clamp recordings were performed on wild type and transgenic embryonic hippocampal neurons maintained in culture for 13–15 DIV. During recordings cells were bathed in a standard external solution containing (in mM): 125 NaCl, 5 KCl, 1.2 MgSO4, 1.2 KH2PO4, 2 CaCl2, 6 glucose, and 25 HEPES-NaOH, pH 7.4. Recording pipettes were fabricated from borosilicate glass capillary using an horizontal puller (Sutter Instruments) inducing tip resistances of 3–5 MΩ and filled with a standard intracellular solution containing (in mM): 130 Cs-gluconate, 8 CsCl, 2 NaCl, 4 EGTA, 10 HEPES- NaOH, 2 MgCl2, 4 MgATP, and 0.3 Tris-GTP. For miniature AMPA-EPSC recordings tetrodotoxin 1µM, Bicuculline 20 μM and AP5 50 μM (Tocris) were added to standard extracellular solution to block the spontaneous action potentials propagation, GABA-A and NMDA receptors, respectively. Recordings were performed at room temperature in voltage clamp mode at holding potential of −70 mV using a Multiclamp 700B amplifier (Molecular Devices) and pClamp-10 software (Axon Instruments, Foster City, CA). Series resistance ranged from 10 to 20 MΩ and was monitored for consistency during recordings. Cells in culture with leak currents &gt; 100 pA were excluded from the analysis. Signals were amplified, sampled at 10 kHz, filtered to 2 or 3 KHz, and analyzed using pClamp 10 data acquisition and analysis program. Electrophysiological mEPSC recordings of neurons WT, IL-1R8 KO and IL-1R8 KO IL-1R KO were always performed in the same experimental sessions.</p><p>Chemical Long Term Potentiation (LTP) was performed as in (<xref ref-type="bibr" rid="bib54">Menna et al., 2013</xref>). Induction was performed stimulating synaptic NMDA receptors via glycine. For glycine-induced LTP experiments, hippocampal neurons were transfected at 10DIV with cDNA encoding for EGFP by using Lipofectamine 2000. After 6 days, cells were perfused with a solution containing (in mM) 125 NaCl, 5 KCl, 1.2 KH2PO4, 2 CaCl2, 1MgCl2, 6 glucose, and 25 HEPES-NaOH, TTX 0.001, Strychnine 0.001 and bicuculline methiodide 0.02 (pH 7.4, KRH) for 10 min then a solution devoid of Mg2+ and containing glycine (100 µM) was applied for 3 min followed by a wash and recovery in neuronal medium for at least 60 min. After 60 minutes cells were immediately fixed and stained. For patch clamp electrophysiology, the patch pipette electrode contained the following solution (in mM): 130 CsGluconate, 8 CsCl, 2 NaCl, 10 HEPES, 4 EGTA, 4 MgATP and 0.3 Tris-GTP.</p></sec><sec id="s4-7"><title>WB analysis</title><p>Samples containing 25 mg protein were resolved in 12% sodium dodecyl sulphate-polyacrylamide gels under reducing conditions. After transfer onto polyvinylidene diflouride membranes for 2 hr at 250 mA at 41C, blots were blocked for 1 hr at room temperature in a 5% MILK solution in phosphate-buffered saline (PBS) pH 7.4 and then incubated with PSD95 (1:10000; monoclonal; UC Davis/NIH NeuroMab Facility, CA), MeCP2 (1:1000; polyclonal; Cell Signaling), GAPDH (1:4000; polyclonal; Synaptic System, Goettingen, Germany) at 4°C overnight in PBS 0.5% Tween-20 (PBS-T). Subsequently, membranes were washed and incubated for 1 hr at room temperature in PBS-T with the secondary antibodies. Western blotting was performed by means of Chemi-Doc system + Image Lab software (Bio-Rad). Photographic development was by chemiluminescence (ECL, Amersham Bioscience or Immobilon substrate, Millipore). Western blot bands were quantified by the ImageJ program (rsb.info.nih.gov/ij).</p></sec><sec id="s4-8"><title>Transcriptomics and bioinformatic analyses</title><p>Total RNA from cortex from individual mice was isolated using TRI (#T9424; Sigma, Inc) and resuspended in 100 ul ddH2O treated with diethyl pyrocarbonate (DEPC). Samples were then incubated with DNase I (#79254; Qiagen, Inc) for 10 min at room temperature and precipitated with RNA grade potassium acetyate (Ambion, #AM9610). RNA pellets were finally resuspended in 20 ul ddH2O DEPC. Stranded mRNA-Seq multiplexed libraries were prepared from total RNA from mouse cortex following manufacturer’s instructions (Illumina, Inc). To reduce biological variability, each library was performed with total RNA from three independent mice. A total of 3 libraries (9 mice in total) were performed per condition (12 libraries in total). Conditions were wild-type mice (C57bl/6j mice), wild-type mice treated with IL1β 8 μg/kg o.n. (14 hr), IL-1R8 KO mice and IL-1R8 KO mice treated with Anakinra (30 mg/kg, i.p. administration) for three consecutive days. Sequencing was performed in a HiSeq 2500 apparatus in paired-end configuration (2 × 125 bp). To increase sequencing depth, samples were sequenced in two different lanes. All the libraries were loaded in each of the two lanes. Quality control of the raw data was performed with FastQC (<ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>). Libraries were trimmed for adapter removal using Trimmomatic (<xref ref-type="bibr" rid="bib9">Bolger et al., 2014</xref>) and mapped to reference genome (Ensembl GRCm38) using TopHat2 (<xref ref-type="bibr" rid="bib45">Kim et al., 2013</xref>) and Bowtie2 (<xref ref-type="bibr" rid="bib48">Langmead et al., 2009</xref>). Library sizes of primary mapped reads were between 70 and 96 million reads. Samtools was used to manipulate BAM files (<xref ref-type="bibr" rid="bib51">Li et al., 2009</xref>). For calling of differentially expressed genes (DEG), mapped reads were counted with HTSeq v0.6.1 (<xref ref-type="bibr" rid="bib2">Anders et al., 2015</xref>) and count tables were analysed using DeSeq2 v1.10.1 R-package (<xref ref-type="bibr" rid="bib52">Love et al., 2014</xref>) with a design of one factor with four levels (‘wild-type’, ‘wild-type + IL1β”, ‘IL1-R8 KO’, ‘IL1-R8 KO + Anakinra’) and differences between groups were tested using contrasts for wild-type + IL1β versus wild-type; IL-1R8 KO versus wild-type; IL-1R8 KO + Anakinra versus wild-type. For consideration of differentially regulated genes between conditions, we used adjusted p-value&lt;0.1 or adjusted p-value&lt;0.05 as indicated in figure legends. Functional annotation and category and pathway analysis were carried out using WEB-based Gene SeT AnaLysis Toolkit (WebGestalt) (<xref ref-type="bibr" rid="bib89">Zhang et al., 2005</xref>). All expression data are made publicly available in the GEO Series GSE80446.</p></sec><sec id="s4-9"><title>Statistical analysis</title><p>Data are presented as mean±standard error (SE) from the indicated number of experiments. Statistical analysis was performed using PRISM 6 software (GraphPad, Software Inc., San Diego,CA, USA). After testing whether data were normally distributed or not, the appropriate statistical test has been used. The Kolmogorov –Smirnov test was used to determine significance in cumulative distributions of mEPSC amplitudes and integrated density values. In particular, Mann-Whitney <italic>t</italic> test was used to determine significance in an average of mEPSC frequency. To determine significant differences in spine number we used Mann Whitney test or one-way ANOVA followed by specific multiple comparison post hoc tests (as indicated). The differences were considered to be significant if p≤0.05 and are indicated by (*) or (#); those at p≤0.01 are indicated by double (*) or (#); those at p≤0.005 are indicated by triple (*) or (#); those at p≤0.0001 by four (*) or (#).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Camilla Tafuro, Mattia Aime, Marilyn Scandaglia and Martina Molgora for help in some experiments. We are grateful to Dr. Michael Greenberg (Department of Microbiology and Molecular Genetics at Harvard Medical School) for shCTRL and shMeCP2 constructs. Work in our lab is supported by Cariplo 2012–0560, Ministero della Salute GR-2011–02347377, CARIPLO 2015–0594, to MM and by Cariplo 2015–0952 to RT. RT was previously supported by a Fondazione Umberto Veronesi Fellowship. IC is supported by a Fondazione Giancarla Vollaro Fellowship. JPLA is supported by grant SAF2014-60233-JIN from the Ministerio de Economía y Competitividad (MINECO) co-financed by the European Regional Development Fund (ERDF). AB is supported by grants SAF2014-56197-R, SEV-2013-0317 and PCIN-2015-192-C02-01 from MINECO co-financed by the European Regional Development Fund (ERDF). AM acknolewledges a grant from Fondazione Cariplo (Contract n. 2015-0564)</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>RT, Conceptualization, Data curation, Formal analysis, Investigation, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>RM, Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con3"><p>JPL-A, Conceptualization, Data curation, Formal analysis</p></fn><fn fn-type="con" id="con4"><p>IC, Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con5"><p>AC, Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con6"><p>MR, Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con7"><p>CM, Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con8"><p>DP, Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con9"><p>CG, Conceptualization, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con10"><p>AM, Conceptualization, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con11"><p>EM, Conceptualization, Data curation, Formal analysis, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con12"><p>AB, Data curation, Formal analysis, Writing—original draft</p></fn><fn fn-type="con" id="con13"><p>MM, Conceptualization, Data curation, Supervision, Funding acquisition, Writing—original draft, Project administration, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All the experimental procedures followed the guidelines established by the European Legislation (Directive 2010/63/EU), and the Italian Legislation (L.D. no 26/2014).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="SD1-data"><object-id pub-id-type="doi">10.7554/eLife.21735.014</object-id><label>Supplementary file 1.</label><caption><title>Differentially expressed mRNAs in the hippocampus of IL-1β treated mice</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.014">http://dx.doi.org/10.7554/eLife.21735.014</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-21735-supp1-v1.xlsx"/></supplementary-material><supplementary-material id="SD2-data"><object-id pub-id-type="doi">10.7554/eLife.21735.015</object-id><label>Supplementary file 2.</label><caption><title>Differentially expressed mRNAs in the hippocampus of IL-1R8 (aka TIR8) KO mice</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.015">http://dx.doi.org/10.7554/eLife.21735.015</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-21735-supp2-v1.xlsx"/></supplementary-material><supplementary-material id="SD3-data"><object-id pub-id-type="doi">10.7554/eLife.21735.016</object-id><label>Supplementary file 3.</label><caption><title>Genes differentially expressed in the hippocampus of both IL-1β treated mice and IL-1R8 (aka TIR8) KO.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.016">http://dx.doi.org/10.7554/eLife.21735.016</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-21735-supp3-v1.xlsx"/></supplementary-material><supplementary-material id="SD4-data"><object-id pub-id-type="doi">10.7554/eLife.21735.017</object-id><label>Supplementary file 4.</label><caption><p>(<bold>A</bold>) Webgestalt GO-Biological process enrichment analysis for genes differentially expressed after treatment with IL-1β (see <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1</xref>). (<bold>B</bold>) Webgestalt GO-Biological process enrichment analysis for genes differentially expressed in IL-1R8 KO mice (see <xref ref-type="supplementary-material" rid="SD2-data">Supplementary file 2</xref>). (<bold>C</bold>) Full Webgestalt GO enrichment analysis (BP, MF and CC) for genes differentially expressed both in IL-1R8 KO mice and in IL-1β treated mice (see <xref ref-type="supplementary-material" rid="SD3-data">Supplementary file 3</xref>).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.017">http://dx.doi.org/10.7554/eLife.21735.017</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-21735-supp4-v1.xlsx"/></supplementary-material><supplementary-material id="SD5-data"><object-id pub-id-type="doi">10.7554/eLife.21735.018</object-id><label>Supplementary file 5.</label><caption><title>Raw data of all the values used for graphics in the different panels.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.018">http://dx.doi.org/10.7554/eLife.21735.018</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-21735-supp5-v1.xlsx"/></supplementary-material><supplementary-material id="SD6-data"><object-id pub-id-type="doi">10.7554/eLife.21735.019</object-id><label>Supplementary file 6.</label><caption><title>Statistic analysis of the graphics in the different panels.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.019">http://dx.doi.org/10.7554/eLife.21735.019</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-21735-supp6-v1.xlsx"/></supplementary-material><sec id="s7" sec-type="datasets"><title>Major datasets</title><p>The following dataset was generated:</p><p><related-object content-type="generated-dataset" id="data-ro1" source-id="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80446" source-id-type="uri"><collab>Romana Tomasoni</collab><x>,</x> <collab>Jose P Lopez-Atalaya</collab><x>,</x> <collab>Angel Barco</collab><x>,</x> <collab>Michela Matteoli</collab><x>,</x> <year>2017</year><x>,</x><source>Quantitative Analysis of cortical transcriptomes through Next Generation Sequencing from wild-type mice, wild-type mice treated with IL1b, IL-1R8 KO mice and IL-1R8 KO mice treated with IL1b antagonist Anakinra</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80446">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80446</ext-link><x>,</x> <comment>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE80446</comment></related-object></p></sec></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amir</surname><given-names>RE</given-names></name><name><surname>Van den Veyver</surname><given-names>IB</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>CQ</given-names></name><name><surname>Francke</surname><given-names>U</given-names></name><name><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2</article-title><source>Nature Genetics</source><volume>23</volume><fpage>185</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1038/13810</pub-id><pub-id pub-id-type="pmid">10508514</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Pyl</surname><given-names>PT</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HTSeq--a Python framework to work with high-throughput sequencing data</article-title><source>Bioinformatics</source><volume>31</volume><fpage>166</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu638</pub-id><pub-id pub-id-type="pmid">25260700</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asaka</surname><given-names>Y</given-names></name><name><surname>Jugloff</surname><given-names>DG</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Eubanks</surname><given-names>JH</given-names></name><name><surname>Fitzsimonds</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of rett syndrome</article-title><source>Neurobiology of Disease</source><volume>21</volume><fpage>217</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2005.07.005</pub-id><pub-id pub-id-type="pmid">16087343</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avital</surname><given-names>A</given-names></name><name><surname>Goshen</surname><given-names>I</given-names></name><name><surname>Kamsler</surname><given-names>A</given-names></name><name><surname>Segal</surname><given-names>M</given-names></name><name><surname>Iverfeldt</surname><given-names>K</given-names></name><name><surname>Richter-Levin</surname><given-names>G</given-names></name><name><surname>Yirmiya</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Impaired interleukin-1 signaling is associated with deficits in hippocampal memory processes and neural plasticity</article-title><source>Hippocampus</source><volume>13</volume><fpage>826</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1002/hipo.10135</pub-id><pub-id pub-id-type="pmid">14620878</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrientos</surname><given-names>RM</given-names></name><name><surname>Frank</surname><given-names>MG</given-names></name><name><surname>Hein</surname><given-names>AM</given-names></name><name><surname>Higgins</surname><given-names>EA</given-names></name><name><surname>Watkins</surname><given-names>LR</given-names></name><name><surname>Rudy</surname><given-names>JW</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Time course of hippocampal IL-1 beta and memory consolidation impairments in aging rats following peripheral infection</article-title><source>Brain, Behavior, and Immunity</source><volume>23</volume><fpage>46</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2008.07.002</pub-id><pub-id pub-id-type="pmid">18664380</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batliwalla</surname><given-names>FM</given-names></name><name><surname>Baechler</surname><given-names>EC</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Balasubramanian</surname><given-names>S</given-names></name><name><surname>Khalili</surname><given-names>H</given-names></name><name><surname>Damle</surname><given-names>A</given-names></name><name><surname>Ortmann</surname><given-names>WA</given-names></name><name><surname>Perrone</surname><given-names>A</given-names></name><name><surname>Kantor</surname><given-names>AB</given-names></name><name><surname>Gulko</surname><given-names>PS</given-names></name><name><surname>Kern</surname><given-names>M</given-names></name><name><surname>Furie</surname><given-names>R</given-names></name><name><surname>Behrens</surname><given-names>TW</given-names></name><name><surname>Gregersen</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Peripheral blood gene expression profiling in rheumatoid arthritis</article-title><source>Genes and Immunity</source><volume>6</volume><fpage>388</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1038/sj.gene.6364209</pub-id><pub-id pub-id-type="pmid">15973463</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedogni</surname><given-names>F</given-names></name><name><surname>Cobolli Gigli</surname><given-names>C</given-names></name><name><surname>Pozzi</surname><given-names>D</given-names></name><name><surname>Rossi</surname><given-names>RL</given-names></name><name><surname>Scaramuzza</surname><given-names>L</given-names></name><name><surname>Rossetti</surname><given-names>G</given-names></name><name><surname>Pagani</surname><given-names>M</given-names></name><name><surname>Kilstrup-Nielsen</surname><given-names>C</given-names></name><name><surname>Matteoli</surname><given-names>M</given-names></name><name><surname>Landsberger</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Defects during Mecp2 null embryonic cortex development precede the onset of overt neurological symptoms</article-title><source>Cerebral Cortex</source><volume>26</volume><fpage>2517</fpage><lpage>2529</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhv078</pub-id><pub-id pub-id-type="pmid">25979088</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackman</surname><given-names>MP</given-names></name><name><surname>Djukic</surname><given-names>B</given-names></name><name><surname>Nelson</surname><given-names>SB</given-names></name><name><surname>Turrigiano</surname><given-names>GG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A critical and cell-autonomous role for MeCP2 in synaptic scaling up</article-title><source>Journal of Neuroscience</source><volume>32</volume><fpage>13529</fpage><lpage>13536</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3077-12.2012</pub-id><pub-id pub-id-type="pmid">23015442</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolger</surname><given-names>AM</given-names></name><name><surname>Lohse</surname><given-names>M</given-names></name><name><surname>Usadel</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Trimmomatic: a flexible trimmer for illumina sequence data</article-title><source>Bioinformatics</source><volume>30</volume><fpage>2114</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id><pub-id pub-id-type="pmid">24695404</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calderón</surname><given-names>J</given-names></name><name><surname>Flores</surname><given-names>P</given-names></name><name><surname>Babul</surname><given-names>M</given-names></name><name><surname>Aguirre</surname><given-names>JM</given-names></name><name><surname>Slachevsky</surname><given-names>A</given-names></name><name><surname>Padilla</surname><given-names>O</given-names></name><name><surname>Scoriels</surname><given-names>L</given-names></name><name><surname>Henríquez</surname><given-names>C</given-names></name><name><surname>Cárcamo</surname><given-names>C</given-names></name><name><surname>Bravo-Zehnder</surname><given-names>M</given-names></name><name><surname>González</surname><given-names>A</given-names></name><name><surname>Massardo</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Systemic lupus erythematosus impairs memory cognitive tests not affected by depression</article-title><source>Lupus</source><volume>23</volume><fpage>1042</fpage><lpage>1053</lpage><pub-id pub-id-type="doi">10.1177/0961203314536247</pub-id><pub-id pub-id-type="pmid">24879658</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chahrour</surname><given-names>M</given-names></name><name><surname>Jung</surname><given-names>SY</given-names></name><name><surname>Shaw</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Wong</surname><given-names>ST</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>MeCP2, a key contributor to neurological disease, activates and represses transcription</article-title><source>Science</source><volume>320</volume><fpage>1224</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1126/science.1153252</pub-id><pub-id pub-id-type="pmid">18511691</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chahrour</surname><given-names>M</given-names></name><name><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The story of rett syndrome: from clinic to neurobiology</article-title><source>Neuron</source><volume>56</volume><fpage>422</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2007.10.001</pub-id><pub-id pub-id-type="pmid">17988628</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>HT</given-names></name><name><surname>Zoghbi</surname><given-names>HY</given-names></name><name><surname>Rosenmund</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number</article-title><source>Neuron</source><volume>56</volume><fpage>58</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2007.08.018</pub-id><pub-id pub-id-type="pmid">17920015</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chugh</surname><given-names>D</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Afjei</surname><given-names>SA</given-names></name><name><surname>Bakochi</surname><given-names>A</given-names></name><name><surname>Ekdahl</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Brain inflammation induces post-synaptic changes during early synapse formation in adult-born hippocampal neurons</article-title><source>Experimental Neurology</source><volume>250</volume><fpage>176</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2013.09.005</pub-id><pub-id pub-id-type="pmid">24047952</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>AL</given-names></name><name><surname>Levenson</surname><given-names>JM</given-names></name><name><surname>Vilaythong</surname><given-names>AP</given-names></name><name><surname>Richman</surname><given-names>R</given-names></name><name><surname>Armstrong</surname><given-names>DL</given-names></name><name><surname>Noebels</surname><given-names>JL</given-names></name><name><surname>David Sweatt</surname><given-names>J</given-names></name><name><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mild overexpression of MeCP2 causes a progressive neurological disorder in mice</article-title><source>Human Molecular Genetics</source><volume>13</volume><fpage>2679</fpage><lpage>2689</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddh282</pub-id><pub-id pub-id-type="pmid">15351775</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coogan</surname><given-names>AN</given-names></name><name><surname>O'Connor</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Interleukin-1beta inhibits a tetraethylammonium-induced synaptic potentiation in the rat dentate gyrus in vitro</article-title><source>European Journal of Pharmacology</source><volume>374</volume><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(99)00320-9</pub-id><pub-id pub-id-type="pmid">10422760</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corradini</surname><given-names>I</given-names></name><name><surname>Donzelli</surname><given-names>A</given-names></name><name><surname>Antonucci</surname><given-names>F</given-names></name><name><surname>Welzl</surname><given-names>H</given-names></name><name><surname>Loos</surname><given-names>M</given-names></name><name><surname>Martucci</surname><given-names>R</given-names></name><name><surname>De Astis</surname><given-names>S</given-names></name><name><surname>Pattini</surname><given-names>L</given-names></name><name><surname>Inverardi</surname><given-names>F</given-names></name><name><surname>Wolfer</surname><given-names>D</given-names></name><name><surname>Caleo</surname><given-names>M</given-names></name><name><surname>Bozzi</surname><given-names>Y</given-names></name><name><surname>Verderio</surname><given-names>C</given-names></name><name><surname>Frassoni</surname><given-names>C</given-names></name><name><surname>Braida</surname><given-names>D</given-names></name><name><surname>Clerici</surname><given-names>M</given-names></name><name><surname>Lipp</surname><given-names>HP</given-names></name><name><surname>Sala</surname><given-names>M</given-names></name><name><surname>Matteoli</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Epileptiform activity and cognitive deficits in SNAP-25(+/-) mice are normalized by antiepileptic drugs</article-title><source>Cerebral Cortex</source><volume>24</volume><fpage>364</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhs316</pub-id><pub-id pub-id-type="pmid">23064108</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costello</surname><given-names>DA</given-names></name><name><surname>Watson</surname><given-names>MB</given-names></name><name><surname>Cowley</surname><given-names>TR</given-names></name><name><surname>Murphy</surname><given-names>N</given-names></name><name><surname>Murphy Royal</surname><given-names>C</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Lynch</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Interleukin-1alpha and HMGB1 mediate hippocampal dysfunction in SIGIRR-deficient mice</article-title><source>Journal of Neuroscience</source><volume>31</volume><fpage>3871</fpage><lpage>3879</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.6676-10.2011</pub-id><pub-id pub-id-type="pmid">21389242</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costelloe</surname><given-names>C</given-names></name><name><surname>Watson</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>A</given-names></name><name><surname>McQuillan</surname><given-names>K</given-names></name><name><surname>Loscher</surname><given-names>C</given-names></name><name><surname>Armstrong</surname><given-names>ME</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>O'Neill</surname><given-names>LA</given-names></name><name><surname>Mills</surname><given-names>KH</given-names></name><name><surname>Lynch</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>IL-1F5 mediates anti-inflammatory activity in the brain through induction of IL-4 following interaction with SIGIRR/TIR8</article-title><source>Journal of Neurochemistry</source><volume>105</volume><fpage>1960</fpage><lpage>1969</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05304.x</pub-id><pub-id pub-id-type="pmid">18284608</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deacon</surname><given-names>RM</given-names></name><name><surname>Rawlins</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>T-maze alternation in the rodent</article-title><source>Nature Protocols</source><volume>1</volume><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.2</pub-id><pub-id pub-id-type="pmid">17406205</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deverman</surname><given-names>BE</given-names></name><name><surname>Patterson</surname><given-names>PH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cytokines and CNS development</article-title><source>Neuron</source><volume>64</volume><fpage>61</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2009.09.002</pub-id><pub-id pub-id-type="pmid">19840550</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Immunological and inflammatory functions of the interleukin-1 family</article-title><source>Annual Review of Immunology</source><volume>27</volume><fpage>519</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.021908.132612</pub-id><pub-id pub-id-type="pmid">19302047</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drexler</surname><given-names>SK</given-names></name><name><surname>Kong</surname><given-names>P</given-names></name><name><surname>Inglis</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>RO</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Yazdi</surname><given-names>AS</given-names></name><name><surname>Brennan</surname><given-names>F</given-names></name><name><surname>Feldmann</surname><given-names>M</given-names></name><name><surname>Foxwell</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>SIGIRR/TIR-8 is an inhibitor of Toll-like receptor signaling in primary human cells and regulates inflammation in models of rheumatoid arthritis</article-title><source>Arthritis &amp; Rheumatism</source><volume>62</volume><fpage>2249</fpage><lpage>2261</lpage><pub-id pub-id-type="doi">10.1002/art.27517</pub-id><pub-id pub-id-type="pmid">20506350</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>MG</given-names></name><name><surname>Barrientos</surname><given-names>RM</given-names></name><name><surname>Hein</surname><given-names>AM</given-names></name><name><surname>Biedenkapp</surname><given-names>JC</given-names></name><name><surname>Watkins</surname><given-names>LR</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>IL-1RA blocks E. coli-induced suppression of arc and long-term memory in aged F344xBN F1 rats</article-title><source>Brain, Behavior, and Immunity</source><volume>24</volume><fpage>254</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2009.10.005</pub-id><pub-id pub-id-type="pmid">19822205</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gangisetty</surname><given-names>O</given-names></name><name><surname>Bekdash</surname><given-names>R</given-names></name><name><surname>Maglakelidze</surname><given-names>G</given-names></name><name><surname>Sarkar</surname><given-names>DK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Fetal alcohol exposure alters proopiomelanocortin gene expression and hypothalamic-pituitary-adrenal axis function via increasing MeCP2 expression in the hypothalamus</article-title><source>PLoS One</source><volume>9</volume><elocation-id>e113228</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0113228</pub-id><pub-id pub-id-type="pmid">25409090</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013a</year><article-title>The interleukin-1 family: back to the future</article-title><source>Immunity</source><volume>39</volume><fpage>1003</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.11.010</pub-id><pub-id pub-id-type="pmid">24332029</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Riva</surname><given-names>F</given-names></name><name><surname>Bonavita</surname><given-names>E</given-names></name><name><surname>Gentile</surname><given-names>S</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013b</year><article-title>Decoys and regulatory &quot;Receptors&quot; of the IL-1/Toll-Like Receptor Superfamily</article-title><source>Frontiers in Immunology</source><volume>4</volume><elocation-id>180</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2013.00180</pub-id><pub-id pub-id-type="pmid">23847621</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Riva</surname><given-names>F</given-names></name><name><surname>Polentarutti</surname><given-names>N</given-names></name><name><surname>Buracchi</surname><given-names>C</given-names></name><name><surname>Sironi</surname><given-names>M</given-names></name><name><surname>De Bortoli</surname><given-names>M</given-names></name><name><surname>Muzio</surname><given-names>M</given-names></name><name><surname>Bergottini</surname><given-names>R</given-names></name><name><surname>Scanziani</surname><given-names>E</given-names></name><name><surname>Vecchi</surname><given-names>A</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family</article-title><source>PNAS</source><volume>101</volume><fpage>3522</fpage><lpage>3526</lpage><pub-id pub-id-type="doi">10.1073/pnas.0308680101</pub-id><pub-id pub-id-type="pmid">14993616</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Riva</surname><given-names>F</given-names></name><name><surname>Veliz</surname><given-names>T</given-names></name><name><surname>Polentarutti</surname><given-names>N</given-names></name><name><surname>Pasqualini</surname><given-names>F</given-names></name><name><surname>Radaelli</surname><given-names>E</given-names></name><name><surname>Sironi</surname><given-names>M</given-names></name><name><surname>Nebuloni</surname><given-names>M</given-names></name><name><surname>Zorini</surname><given-names>EO</given-names></name><name><surname>Scanziani</surname><given-names>E</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Increased susceptibility to colitis-associated Cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family</article-title><source>Cancer Research</source><volume>67</volume><fpage>6017</fpage><lpage>6021</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-0560</pub-id><pub-id pub-id-type="pmid">17616656</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldbach-Mansky</surname><given-names>R</given-names></name><name><surname>Dailey</surname><given-names>NJ</given-names></name><name><surname>Canna</surname><given-names>SW</given-names></name><name><surname>Gelabert</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>J</given-names></name><name><surname>Rubin</surname><given-names>BI</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Brewer</surname><given-names>C</given-names></name><name><surname>Zalewski</surname><given-names>C</given-names></name><name><surname>Wiggs</surname><given-names>E</given-names></name><name><surname>Hill</surname><given-names>S</given-names></name><name><surname>Turner</surname><given-names>ML</given-names></name><name><surname>Karp</surname><given-names>BI</given-names></name><name><surname>Aksentijevich</surname><given-names>I</given-names></name><name><surname>Pucino</surname><given-names>F</given-names></name><name><surname>Penzak</surname><given-names>SR</given-names></name><name><surname>Haverkamp</surname><given-names>MH</given-names></name><name><surname>Stein</surname><given-names>L</given-names></name><name><surname>Adams</surname><given-names>BS</given-names></name><name><surname>Moore</surname><given-names>TL</given-names></name><name><surname>Fuhlbrigge</surname><given-names>RC</given-names></name><name><surname>Shaham</surname><given-names>B</given-names></name><name><surname>Jarvis</surname><given-names>JN</given-names></name><name><surname>O'Neil</surname><given-names>K</given-names></name><name><surname>Vehe</surname><given-names>RK</given-names></name><name><surname>Beitz</surname><given-names>LO</given-names></name><name><surname>Gardner</surname><given-names>G</given-names></name><name><surname>Hannan</surname><given-names>WP</given-names></name><name><surname>Warren</surname><given-names>RW</given-names></name><name><surname>Horn</surname><given-names>W</given-names></name><name><surname>Cole</surname><given-names>JL</given-names></name><name><surname>Paul</surname><given-names>SM</given-names></name><name><surname>Hawkins</surname><given-names>PN</given-names></name><name><surname>Pham</surname><given-names>TH</given-names></name><name><surname>Snyder</surname><given-names>C</given-names></name><name><surname>Wesley</surname><given-names>RA</given-names></name><name><surname>Hoffmann</surname><given-names>SC</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>Butman</surname><given-names>JA</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition</article-title><source>New England Journal of Medicine</source><volume>355</volume><fpage>581</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa055137</pub-id><pub-id pub-id-type="pmid">16899778</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldbach-Mansky</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Current status of understanding the pathogenesis and management of patients with NOMID/CINCA</article-title><source>Current Rheumatology Reports</source><volume>13</volume><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1007/s11926-011-0165-y</pub-id><pub-id pub-id-type="pmid">21538043</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabrucker</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A role for synaptic zinc in ProSAP/Shank PSD scaffold malformation in autism spectrum disorders</article-title><source>Developmental Neurobiology</source><volume>74</volume><fpage>136</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1002/dneu.22089</pub-id><pub-id pub-id-type="pmid">23650259</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Synaptopathies: diseases of the synaptome</article-title><source>Current Opinion in Neurobiology</source><volume>22</volume><fpage>522</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2012.02.002</pub-id><pub-id pub-id-type="pmid">22409856</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulen</surname><given-names>MF</given-names></name><name><surname>Kang</surname><given-names>Z</given-names></name><name><surname>Bulek</surname><given-names>K</given-names></name><name><surname>Youzhong</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>TW</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Altuntas</surname><given-names>CZ</given-names></name><name><surname>Sass Bak-Jensen</surname><given-names>K</given-names></name><name><surname>McGeachy</surname><given-names>MJ</given-names></name><name><surname>Do</surname><given-names>JS</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Delgoffe</surname><given-names>GM</given-names></name><name><surname>Min</surname><given-names>B</given-names></name><name><surname>Powell</surname><given-names>JD</given-names></name><name><surname>Tuohy</surname><given-names>VK</given-names></name><name><surname>Cua</surname><given-names>DJ</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation</article-title><source>Immunity</source><volume>32</volume><fpage>54</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.12.003</pub-id><pub-id pub-id-type="pmid">20060329</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guy</surname><given-names>J</given-names></name><name><surname>Gan</surname><given-names>J</given-names></name><name><surname>Selfridge</surname><given-names>J</given-names></name><name><surname>Cobb</surname><given-names>S</given-names></name><name><surname>Bird</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Reversal of neurological defects in a mouse model of Rett syndrome</article-title><source>Science</source><volume>315</volume><fpage>1143</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1126/science.1138389</pub-id><pub-id pub-id-type="pmid">17289941</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagberg</surname><given-names>H</given-names></name><name><surname>Gressens</surname><given-names>P</given-names></name><name><surname>Mallard</surname><given-names>C</given-names></name><name><surname>fetal</surname><given-names>Iduring</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults</article-title><source>Annals of Neurology</source><volume>71</volume><fpage>444</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1002/ana.22620</pub-id><pub-id pub-id-type="pmid">22334391</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hein</surname><given-names>AM</given-names></name><name><surname>Stasko</surname><given-names>MR</given-names></name><name><surname>Matousek</surname><given-names>SB</given-names></name><name><surname>Scott-McKean</surname><given-names>JJ</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Olschowka</surname><given-names>JA</given-names></name><name><surname>Costa</surname><given-names>AC</given-names></name><name><surname>O'Banion</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sustained hippocampal IL-1beta overexpression impairs contextual and spatial memory in transgenic mice</article-title><source>Brain, Behavior, and Immunity</source><volume>24</volume><fpage>243</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2009.10.002</pub-id><pub-id pub-id-type="pmid">19825412</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoeffer</surname><given-names>CA</given-names></name><name><surname>Klann</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>mTOR signaling: at the crossroads of plasticity, memory and disease</article-title><source>Trends in Neurosciences</source><volume>33</volume><fpage>67</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2009.11.003</pub-id><pub-id pub-id-type="pmid">19963289</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husted</surname><given-names>JA</given-names></name><name><surname>Thavaneswaran</surname><given-names>A</given-names></name><name><surname>Chandran</surname><given-names>V</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis</article-title><source>The Journal of Rheumatology</source><volume>40</volume><fpage>1349</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.3899/jrheum.121500</pub-id><pub-id pub-id-type="pmid">23772076</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>R</given-names></name><name><surname>Verhard</surname><given-names>E</given-names></name><name><surname>Lankester</surname><given-names>A</given-names></name><name><surname>Ten Cate</surname><given-names>R</given-names></name><name><surname>van Dissel</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Enhanced interleukin-1beta and interleukin-18 release in a patient with chronic infantile neurologic, cutaneous, articular syndrome</article-title><source>Arthritis &amp; Rheumatism</source><volume>50</volume><fpage>3329</fpage><lpage>3333</lpage><pub-id pub-id-type="doi">10.1002/art.20494</pub-id><pub-id pub-id-type="pmid">15476236</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaworski</surname><given-names>J</given-names></name><name><surname>Sheng</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The growing role of mTOR in neuronal development and plasticity</article-title><source>Molecular Neurobiology</source><volume>34</volume><fpage>205</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1385/MN:34:3:205</pub-id><pub-id pub-id-type="pmid">17308353</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Ash</surname><given-names>RT</given-names></name><name><surname>Baker</surname><given-names>SA</given-names></name><name><surname>Suter</surname><given-names>B</given-names></name><name><surname>Ferguson</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Rudy</surname><given-names>J</given-names></name><name><surname>Torsky</surname><given-names>SP</given-names></name><name><surname>Chao</surname><given-names>HT</given-names></name><name><surname>Zoghbi</surname><given-names>HY</given-names></name><name><surname>Smirnakis</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dendritic arborization and spine dynamics are abnormal in the mouse model of MECP2 duplication syndrome</article-title><source>Journal of Neuroscience</source><volume>33</volume><fpage>19518</fpage><lpage>19533</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1745-13.2013</pub-id><pub-id pub-id-type="pmid">24336718</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>PL</given-names></name><name><surname>Veenstra</surname><given-names>GJ</given-names></name><name><surname>Wade</surname><given-names>PA</given-names></name><name><surname>Vermaak</surname><given-names>D</given-names></name><name><surname>Kass</surname><given-names>SU</given-names></name><name><surname>Landsberger</surname><given-names>N</given-names></name><name><surname>Strouboulis</surname><given-names>J</given-names></name><name><surname>Wolffe</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription</article-title><source>Nature Genetics</source><volume>19</volume><fpage>187</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1038/561</pub-id><pub-id pub-id-type="pmid">9620779</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khandaker</surname><given-names>GM</given-names></name><name><surname>Cousins</surname><given-names>L</given-names></name><name><surname>Deakin</surname><given-names>J</given-names></name><name><surname>Lennox</surname><given-names>BR</given-names></name><name><surname>Yolken</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>PB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment</article-title><source>The Lancet Psychiatry</source><volume>2</volume><fpage>258</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(14)00122-9</pub-id><pub-id pub-id-type="pmid">26359903</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Pertea</surname><given-names>G</given-names></name><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Pimentel</surname><given-names>H</given-names></name><name><surname>Kelley</surname><given-names>R</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions</article-title><source>Genome Biology</source><volume>14</volume><elocation-id>R36</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2013-14-4-r36</pub-id><pub-id pub-id-type="pmid">23618408</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishi</surname><given-names>N</given-names></name><name><surname>MacDonald</surname><given-names>JL</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Molyneaux</surname><given-names>BJ</given-names></name><name><surname>Azim</surname><given-names>E</given-names></name><name><surname>Macklis</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Reduction of aberrant NF-κB signalling ameliorates Rett syndrome phenotypes in Mecp2-null mice</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>10520</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms10520</pub-id><pub-id pub-id-type="pmid">26821816</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lachmann</surname><given-names>HJ</given-names></name><name><surname>Lowe</surname><given-names>P</given-names></name><name><surname>Felix</surname><given-names>SD</given-names></name><name><surname>Rordorf</surname><given-names>C</given-names></name><name><surname>Leslie</surname><given-names>K</given-names></name><name><surname>Madhoo</surname><given-names>S</given-names></name><name><surname>Wittkowski</surname><given-names>H</given-names></name><name><surname>Bek</surname><given-names>S</given-names></name><name><surname>Hartmann</surname><given-names>N</given-names></name><name><surname>Bosset</surname><given-names>S</given-names></name><name><surname>Hawkins</surname><given-names>PN</given-names></name><name><surname>Jung</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes</article-title><source>The Journal of Experimental Medicine</source><volume>206</volume><fpage>1029</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1084/jem.20082481</pub-id><pub-id pub-id-type="pmid">19364880</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname><given-names>B</given-names></name><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Pop</surname><given-names>M</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Ultrafast and memory-efficient alignment of short DNA sequences to the human genome</article-title><source>Genome Biology</source><volume>10</volume><elocation-id>R25</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2009-10-3-r25</pub-id><pub-id pub-id-type="pmid">19261174</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CC</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Hsu</surname><given-names>KS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/mTOR and Rac1 signaling pathways</article-title><source>Neuropharmacology</source><volume>61</volume><fpage>867</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.06.003</pub-id><pub-id pub-id-type="pmid">21683721</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lepore</surname><given-names>L</given-names></name><name><surname>Paloni</surname><given-names>G</given-names></name><name><surname>Caorsi</surname><given-names>R</given-names></name><name><surname>Alessio</surname><given-names>M</given-names></name><name><surname>Rigante</surname><given-names>D</given-names></name><name><surname>Ruperto</surname><given-names>N</given-names></name><name><surname>Cattalini</surname><given-names>M</given-names></name><name><surname>Tommasini</surname><given-names>A</given-names></name><name><surname>Zulian</surname><given-names>F</given-names></name><name><surname>Ventura</surname><given-names>A</given-names></name><name><surname>Martini</surname><given-names>A</given-names></name><name><surname>Gattorno</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra</article-title><source>The Journal of Pediatrics</source><volume>157</volume><fpage>310</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2010.02.040</pub-id><pub-id pub-id-type="pmid">20472245</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Handsaker</surname><given-names>B</given-names></name><name><surname>Wysoker</surname><given-names>A</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Homer</surname><given-names>N</given-names></name><name><surname>Marth</surname><given-names>G</given-names></name><name><surname>Abecasis</surname><given-names>G</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name><collab>1000 Genome Project Data Processing Subgroup</collab></person-group><year iso-8601-date="2009">2009</year><article-title>The sequence alignment/Map format and SAMtools</article-title><source>Bioinformatics</source><volume>25</volume><fpage>2078</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id><pub-id pub-id-type="pmid">19505943</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lubs</surname><given-names>H</given-names></name><name><surname>Abidi</surname><given-names>F</given-names></name><name><surname>Bier</surname><given-names>JA</given-names></name><name><surname>Abuelo</surname><given-names>D</given-names></name><name><surname>Ouzts</surname><given-names>L</given-names></name><name><surname>Voeller</surname><given-names>K</given-names></name><name><surname>Fennell</surname><given-names>E</given-names></name><name><surname>Stevenson</surname><given-names>RE</given-names></name><name><surname>Schwartz</surname><given-names>CE</given-names></name><name><surname>Arena</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>XLMR syndrome characterized by multiple respiratory infections, hypertelorism, severe CNS deterioration and early death localizes to distal Xq28</article-title><source>American Journal of Medical Genetics</source><volume>85</volume><fpage>243</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19990730)85:3&lt;243::AID-AJMG11&gt;3.0.CO;2-E</pub-id><pub-id pub-id-type="pmid">10398236</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menna</surname><given-names>E</given-names></name><name><surname>Zambetti</surname><given-names>S</given-names></name><name><surname>Morini</surname><given-names>R</given-names></name><name><surname>Donzelli</surname><given-names>A</given-names></name><name><surname>Disanza</surname><given-names>A</given-names></name><name><surname>Calvigioni</surname><given-names>D</given-names></name><name><surname>Braida</surname><given-names>D</given-names></name><name><surname>Nicolini</surname><given-names>C</given-names></name><name><surname>Orlando</surname><given-names>M</given-names></name><name><surname>Fossati</surname><given-names>G</given-names></name><name><surname>Cristina Regondi</surname><given-names>M</given-names></name><name><surname>Pattini</surname><given-names>L</given-names></name><name><surname>Frassoni</surname><given-names>C</given-names></name><name><surname>Francolini</surname><given-names>M</given-names></name><name><surname>Scita</surname><given-names>G</given-names></name><name><surname>Sala</surname><given-names>M</given-names></name><name><surname>Fahnestock</surname><given-names>M</given-names></name><name><surname>Matteoli</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Eps8 controls dendritic spine density and synaptic plasticity through its actin-capping activity</article-title><source>The EMBO Journal</source><volume>32</volume><fpage>1730</fpage><lpage>1744</lpage><pub-id pub-id-type="doi">10.1038/emboj.2013.107</pub-id><pub-id pub-id-type="pmid">23685357</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamae</surname><given-names>T</given-names></name><name><surname>Inaba</surname><given-names>Y</given-names></name><name><surname>Nishimura</surname><given-names>G</given-names></name><name><surname>Kikuchi</surname><given-names>M</given-names></name><name><surname>Kishi</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>R</given-names></name><name><surname>Kaneko</surname><given-names>U</given-names></name><name><surname>Shinoki</surname><given-names>T</given-names></name><name><surname>Imagawa</surname><given-names>T</given-names></name><name><surname>Yokokta</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Effect of anakinra on arthropathy in CINCA/NOMID syndrome</article-title><source>Pediatric Rheumatology</source><volume>8</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.1186/1546-0096-8-9</pub-id><pub-id pub-id-type="pmid">20230645</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mollica</surname><given-names>L</given-names></name><name><surname>De Marchis</surname><given-names>F</given-names></name><name><surname>Spitaleri</surname><given-names>A</given-names></name><name><surname>Dallacosta</surname><given-names>C</given-names></name><name><surname>Pennacchini</surname><given-names>D</given-names></name><name><surname>Zamai</surname><given-names>M</given-names></name><name><surname>Agresti</surname><given-names>A</given-names></name><name><surname>Trisciuoglio</surname><given-names>L</given-names></name><name><surname>Musco</surname><given-names>G</given-names></name><name><surname>Bianchi</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities</article-title><source>Chemistry &amp; Biology</source><volume>14</volume><fpage>431</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2007.03.007</pub-id><pub-id pub-id-type="pmid">17462578</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moretti</surname><given-names>P</given-names></name><name><surname>Levenson</surname><given-names>JM</given-names></name><name><surname>Battaglia</surname><given-names>F</given-names></name><name><surname>Atkinson</surname><given-names>R</given-names></name><name><surname>Teague</surname><given-names>R</given-names></name><name><surname>Antalffy</surname><given-names>B</given-names></name><name><surname>Armstrong</surname><given-names>D</given-names></name><name><surname>Arancio</surname><given-names>O</given-names></name><name><surname>Sweatt</surname><given-names>JD</given-names></name><name><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome</article-title><source>Journal of Neuroscience</source><volume>26</volume><fpage>319</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2623-05.2006</pub-id><pub-id pub-id-type="pmid">16399702</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moy</surname><given-names>SS</given-names></name><name><surname>Nadler</surname><given-names>JJ</given-names></name><name><surname>Young</surname><given-names>NB</given-names></name><name><surname>Nonneman</surname><given-names>RJ</given-names></name><name><surname>Segall</surname><given-names>SK</given-names></name><name><surname>Andrade</surname><given-names>GM</given-names></name><name><surname>Crawley</surname><given-names>JN</given-names></name><name><surname>Magnuson</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Social approach and repetitive behavior in eleven inbred mouse strains</article-title><source>Behavioural Brain Research</source><volume>191</volume><fpage>118</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2008.03.015</pub-id><pub-id pub-id-type="pmid">18440079</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muscal</surname><given-names>E</given-names></name><name><surname>Bloom</surname><given-names>DR</given-names></name><name><surname>Hunter</surname><given-names>JV</given-names></name><name><surname>Myones</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Neurocognitive deficits and neuroimaging abnormalities are prevalent in children with lupus: clinical and research experiences at a US pediatric institution</article-title><source>Lupus</source><volume>19</volume><fpage>268</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1177/0961203309352092</pub-id><pub-id pub-id-type="pmid">20026519</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Na</surname><given-names>ES</given-names></name><name><surname>Nelson</surname><given-names>ED</given-names></name><name><surname>Kavalali</surname><given-names>ET</given-names></name><name><surname>Monteggia</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The impact of MeCP2 loss- or gain-of-function on synaptic plasticity</article-title><source>Neuropsychopharmacology</source><volume>38</volume><fpage>212</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1038/npp.2012.116</pub-id><pub-id pub-id-type="pmid">22781840</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nan</surname><given-names>X</given-names></name><name><surname>Ng</surname><given-names>HH</given-names></name><name><surname>Johnson</surname><given-names>CA</given-names></name><name><surname>Laherty</surname><given-names>CD</given-names></name><name><surname>Turner</surname><given-names>BM</given-names></name><name><surname>Eisenman</surname><given-names>RN</given-names></name><name><surname>Bird</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex</article-title><source>Nature</source><volume>393</volume><fpage>386</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1038/30764</pub-id><pub-id pub-id-type="pmid">9620804</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>ED</given-names></name><name><surname>Kavalali</surname><given-names>ET</given-names></name><name><surname>Monteggia</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>MeCP2-dependent transcriptional repression regulates excitatory neurotransmission</article-title><source>Current Biology</source><volume>16</volume><fpage>710</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2006.02.062</pub-id><pub-id pub-id-type="pmid">16581518</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neven</surname><given-names>B</given-names></name><name><surname>Marvillet</surname><given-names>I</given-names></name><name><surname>Terrada</surname><given-names>C</given-names></name><name><surname>Ferster</surname><given-names>A</given-names></name><name><surname>Boddaert</surname><given-names>N</given-names></name><name><surname>Couloignier</surname><given-names>V</given-names></name><name><surname>Pinto</surname><given-names>G</given-names></name><name><surname>Pagnier</surname><given-names>A</given-names></name><name><surname>Bodemer</surname><given-names>C</given-names></name><name><surname>Bodaghi</surname><given-names>B</given-names></name><name><surname>Tardieu</surname><given-names>M</given-names></name><name><surname>Prieur</surname><given-names>AM</given-names></name><name><surname>Quartier</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome</article-title><source>Arthritis &amp; Rheumatism</source><volume>62</volume><fpage>258</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1002/art.25057</pub-id><pub-id pub-id-type="pmid">20039428</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opazo</surname><given-names>P</given-names></name><name><surname>Watabe</surname><given-names>AM</given-names></name><name><surname>Grant</surname><given-names>SG</given-names></name><name><surname>O'Dell</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Phosphatidylinositol 3-kinase regulates the induction of long-term potentiation through extracellular signal-related kinase-independent mechanisms</article-title><source>Journal of Neuroscience</source><volume>23</volume><fpage>3679</fpage><lpage>3688</lpage><pub-id pub-id-type="pmid">12736339</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Percy</surname><given-names>AK</given-names></name><name><surname>Lane</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Rett syndrome: model of neurodevelopmental disorders</article-title><source>Journal of Child Neurology</source><volume>20</volume><fpage>718</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1177/08830738050200090301</pub-id><pub-id pub-id-type="pmid">16225824</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettem</surname><given-names>KL</given-names></name><name><surname>Yokomaku</surname><given-names>D</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Craig</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Interaction between autism-linked MDGAs and neuroligins suppresses inhibitory synapse development</article-title><source>The Journal of Cell Biology</source><volume>200</volume><fpage>321</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1083/jcb.201206028</pub-id><pub-id pub-id-type="pmid">23358245</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polentarutti</surname><given-names>N</given-names></name><name><surname>Rol</surname><given-names>GP</given-names></name><name><surname>Muzio</surname><given-names>M</given-names></name><name><surname>Bosisio</surname><given-names>D</given-names></name><name><surname>Camnasio</surname><given-names>M</given-names></name><name><surname>Riva</surname><given-names>F</given-names></name><name><surname>Zoja</surname><given-names>C</given-names></name><name><surname>Benigni</surname><given-names>A</given-names></name><name><surname>Tomasoni</surname><given-names>S</given-names></name><name><surname>Vecchi</surname><given-names>A</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Unique pattern of expression and inhibition of IL-1 signaling by the IL-1 receptor family member TIR8/SIGIRR</article-title><source>European Cytokine Network</source><volume>14</volume><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">14715412</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rachal Pugh</surname><given-names>C</given-names></name><name><surname>Fleshner</surname><given-names>M</given-names></name><name><surname>Watkins</surname><given-names>LR</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Rudy</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The immune system and memory consolidation: a role for the cytokine IL-1beta</article-title><source>Neuroscience &amp; Biobehavioral Reviews</source><volume>25</volume><fpage>29</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/S0149-7634(00)00048-8</pub-id><pub-id pub-id-type="pmid">11166076</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramocki</surname><given-names>MB</given-names></name><name><surname>Tavyev</surname><given-names>YJ</given-names></name><name><surname>Peters</surname><given-names>SU</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The MECP2 duplication syndrome</article-title><source>American Journal of Medical Genetics Part A</source><volume>152A</volume><fpage>1079</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.33184</pub-id><pub-id pub-id-type="pmid">20425814</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rees</surname><given-names>L</given-names></name><name><surname>Marshall</surname><given-names>S</given-names></name><name><surname>Hartridge</surname><given-names>C</given-names></name><name><surname>Mackie</surname><given-names>D</given-names></name><name><surname>Weiser</surname><given-names>M</given-names></name><collab>Erabi Group</collab></person-group><year iso-8601-date="2007">2007</year><article-title>Cognitive interventions post acquired brain injury</article-title><source>Brain Injury</source><volume>21</volume><fpage>161</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1080/02699050701201813</pub-id><pub-id pub-id-type="pmid">17364530</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricciardi</surname><given-names>S</given-names></name><name><surname>Boggio</surname><given-names>EM</given-names></name><name><surname>Grosso</surname><given-names>S</given-names></name><name><surname>Lonetti</surname><given-names>G</given-names></name><name><surname>Forlani</surname><given-names>G</given-names></name><name><surname>Stefanelli</surname><given-names>G</given-names></name><name><surname>Calcagno</surname><given-names>E</given-names></name><name><surname>Morello</surname><given-names>N</given-names></name><name><surname>Landsberger</surname><given-names>N</given-names></name><name><surname>Biffo</surname><given-names>S</given-names></name><name><surname>Pizzorusso</surname><given-names>T</given-names></name><name><surname>Giustetto</surname><given-names>M</given-names></name><name><surname>Broccoli</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model</article-title><source>Human Molecular Genetics</source><volume>20</volume><fpage>1182</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddq563</pub-id><pub-id pub-id-type="pmid">21212100</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riva</surname><given-names>F</given-names></name><name><surname>Bonavita</surname><given-names>E</given-names></name><name><surname>Barbati</surname><given-names>E</given-names></name><name><surname>Muzio</surname><given-names>M</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>TIR8/SIGIRR is an Interleukin-1 receptor/Toll like receptor family member with regulatory functions in inflammation and immunity</article-title><source>Frontiers in Immunology</source><volume>3</volume><elocation-id>322</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2012.00322</pub-id><pub-id pub-id-type="pmid">23112799</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothwell</surname><given-names>NJ</given-names></name><name><surname>Luheshi</surname><given-names>GN</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Interleukin 1 in the brain: biology, pathology and therapeutic target</article-title><source>Trends in Neurosciences</source><volume>23</volume><fpage>618</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1016/S0166-2236(00)01661-1</pub-id><pub-id pub-id-type="pmid">11137152</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>R</given-names></name><name><surname>Okano</surname><given-names>M</given-names></name><name><surname>Takena</surname><given-names>H</given-names></name><name><surname>Ohtsuki</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Inhibitory effect of glycyrrhizin on the phosphorylation and DNA-binding abilities of high mobility group proteins 1 and 2 in vitro</article-title><source>Biological &amp; Pharmaceutical Bulletin</source><volume>24</volume><fpage>906</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1248/bpb.24.906</pub-id><pub-id pub-id-type="pmid">11510483</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampath</surname><given-names>V</given-names></name><name><surname>Menden</surname><given-names>H</given-names></name><name><surname>Helbling</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Gastonguay</surname><given-names>A</given-names></name><name><surname>Ramchandran</surname><given-names>R</given-names></name><name><surname>Dimmock</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>SIGIRR genetic variants in premature infants with necrotizing enterocolitis</article-title><source>Pediatrics</source><volume>135</volume><fpage>e1530</fpage><lpage>e1534</lpage><pub-id pub-id-type="doi">10.1542/peds.2014-3386</pub-id><pub-id pub-id-type="pmid">25963006</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarbassov</surname><given-names>DD</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Sengupta</surname><given-names>S</given-names></name><name><surname>Sheen</surname><given-names>JH</given-names></name><name><surname>Hsu</surname><given-names>PP</given-names></name><name><surname>Bagley</surname><given-names>AF</given-names></name><name><surname>Markhard</surname><given-names>AL</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Prolonged rapamycin treatment inhibits mTORC2 assembly and akt/PKB</article-title><source>Molecular Cell</source><volume>22</volume><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2006.03.029</pub-id><pub-id pub-id-type="pmid">16603397</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>H</given-names></name><name><surname>Pitossi</surname><given-names>F</given-names></name><name><surname>Balschun</surname><given-names>D</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>del Rey</surname><given-names>A</given-names></name><name><surname>Besedovsky</surname><given-names>HO</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A neuromodulatory role of interleukin-1beta in the Hippocampus</article-title><source>PNAS</source><volume>95</volume><fpage>7778</fpage><lpage>7783</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.13.7778</pub-id><pub-id pub-id-type="pmid">9636227</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinman</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inflammatory cytokines at the summits of pathological signal cascades in brain diseases</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>pe3</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2003898</pub-id><pub-id pub-id-type="pmid">23322904</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tantra</surname><given-names>M</given-names></name><name><surname>Hammer</surname><given-names>C</given-names></name><name><surname>Kästner</surname><given-names>A</given-names></name><name><surname>Dahm</surname><given-names>L</given-names></name><name><surname>Begemann</surname><given-names>M</given-names></name><name><surname>Bodda</surname><given-names>C</given-names></name><name><surname>Hammerschmidt</surname><given-names>K</given-names></name><name><surname>Giegling</surname><given-names>I</given-names></name><name><surname>Stepniak</surname><given-names>B</given-names></name><name><surname>Castillo Venzor</surname><given-names>A</given-names></name><name><surname>Konte</surname><given-names>B</given-names></name><name><surname>Erbaba</surname><given-names>B</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name><name><surname>Tarami</surname><given-names>A</given-names></name><name><surname>Schulz-Schaeffer</surname><given-names>W</given-names></name><name><surname>Rujescu</surname><given-names>D</given-names></name><name><surname>Mannan</surname><given-names>AU</given-names></name><name><surname>Ehrenreich</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mild expression differences of MECP2 influencing aggressive social behavior</article-title><source>EMBO Molecular Medicine</source><volume>6</volume><fpage>662</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1002/emmm.201303744</pub-id><pub-id pub-id-type="pmid">24648499</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theoharides</surname><given-names>TC</given-names></name><name><surname>Athanassiou</surname><given-names>M</given-names></name><name><surname>Panagiotidou</surname><given-names>S</given-names></name><name><surname>Doyle</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dysregulated brain immunity and neurotrophin signaling in rett syndrome and autism spectrum disorders</article-title><source>Journal of Neuroimmunology</source><volume>279</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2014.12.003</pub-id><pub-id pub-id-type="pmid">25669997</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>L</given-names></name><name><surname>Prieto</surname><given-names>GA</given-names></name><name><surname>Kramár</surname><given-names>EA</given-names></name><name><surname>Smith</surname><given-names>ED</given-names></name><name><surname>Cribbs</surname><given-names>DH</given-names></name><name><surname>Lynch</surname><given-names>G</given-names></name><name><surname>Cotman</surname><given-names>CW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1β via p38 mitogen-activated protein kinase</article-title><source>Journal of Neuroscience</source><volume>32</volume><fpage>17714</fpage><lpage>17724</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1253-12.2012</pub-id><pub-id pub-id-type="pmid">23223292</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Esch</surname><given-names>S</given-names></name><name><surname>Krediet</surname><given-names>RT</given-names></name><name><surname>Struijk</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Prognostic factors for peritonitis outcome</article-title><source>Contributions to Nephrology</source><volume>178</volume><fpage>264</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1159/000337889</pub-id><pub-id pub-id-type="pmid">22652748</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verderio</surname><given-names>C</given-names></name><name><surname>Coco</surname><given-names>S</given-names></name><name><surname>Fumagalli</surname><given-names>G</given-names></name><name><surname>Matteoli</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Spatial changes in calcium signaling during the establishment of neuronal polarity and synaptogenesis</article-title><source>The Journal of Cell Biology</source><volume>126</volume><fpage>1527</fpage><lpage>1536</lpage><pub-id pub-id-type="doi">10.1083/jcb.126.6.1527</pub-id><pub-id pub-id-type="pmid">8089183</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Véliz Rodriguez</surname><given-names>T</given-names></name><name><surname>Moalli</surname><given-names>F</given-names></name><name><surname>Polentarutti</surname><given-names>N</given-names></name><name><surname>Paroni</surname><given-names>M</given-names></name><name><surname>Bonavita</surname><given-names>E</given-names></name><name><surname>Anselmo</surname><given-names>A</given-names></name><name><surname>Nebuloni</surname><given-names>M</given-names></name><name><surname>Mantero</surname><given-names>S</given-names></name><name><surname>Jaillon</surname><given-names>S</given-names></name><name><surname>Bragonzi</surname><given-names>A</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Riva</surname><given-names>F</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Role of Toll interleukin-1 receptor (IL-1R) 8, a negative regulator of IL-1R/Toll-like receptor signaling, in resistance to acute Pseudomonas aeruginosa lung infection</article-title><source>Infection and Immunity</source><volume>80</volume><fpage>100</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1128/IAI.05695-11</pub-id><pub-id pub-id-type="pmid">22025515</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vézina</surname><given-names>C</given-names></name><name><surname>Kudelski</surname><given-names>A</given-names></name><name><surname>Sehgal</surname><given-names>SN</given-names></name></person-group><year iso-8601-date="1975">1975</year><article-title>Rapamycin (AY-22,989), a new antifungal antibiotic. I. taxonomy of the producing streptomycete and isolation of the active principle</article-title><source>The Journal of Antibiotics</source><volume>28</volume><fpage>721</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.28.721</pub-id><pub-id pub-id-type="pmid">1102508</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>MB</given-names></name><name><surname>Costello</surname><given-names>DA</given-names></name><name><surname>Carney</surname><given-names>DG</given-names></name><name><surname>McQuillan</surname><given-names>K</given-names></name><name><surname>Lynch</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>SIGIRR modulates the inflammatory response in the brain</article-title><source>Brain, Behavior, and Immunity</source><volume>24</volume><fpage>985</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2010.04.002</pub-id><pub-id pub-id-type="pmid">20394816</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>A</given-names></name><name><surname>Wasiliew</surname><given-names>P</given-names></name><name><surname>Kracht</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Interleukin-1 (IL-1) pathway</article-title><source>Science Signaling</source><volume>3</volume><elocation-id>cm1</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.3105cm1</pub-id><pub-id pub-id-type="pmid">20086235</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>AM</given-names></name><name><surname>Chakrabarti</surname><given-names>B</given-names></name><name><surname>Roberts</surname><given-names>D</given-names></name><name><surname>Lai</surname><given-names>MC</given-names></name><name><surname>Suckling</surname><given-names>J</given-names></name><name><surname>Baron-Cohen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>From molecules to neural morphology: understanding neuroinflammation in autism spectrum condition</article-title><source>Molecular Autism</source><volume>7</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.1186/s13229-016-0068-x</pub-id><pub-id pub-id-type="pmid">26793298</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Kirov</surname><given-names>S</given-names></name><name><surname>Snoddy</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>WebGestalt: an integrated system for exploring gene sets in various biological contexts</article-title><source>Nucleic Acids Research</source><volume>33</volume><fpage>W741</fpage><lpage>W748</lpage><pub-id pub-id-type="doi">10.1093/nar/gki475</pub-id><pub-id pub-id-type="pmid">15980575</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Schwartz</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Involvement of cytokines in normal CNS development and neurological diseases: recent progress and perspectives</article-title><source>Journal of Neuroscience Research</source><volume>52</volume><fpage>7</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-4547(19980401)52:1&lt;7::AID-JNR2&gt;3.0.CO;2-I</pub-id><pub-id pub-id-type="pmid">9556025</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Hong</surname><given-names>EJ</given-names></name><name><surname>Cohen</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>WN</given-names></name><name><surname>Ho</surname><given-names>HY</given-names></name><name><surname>Schmidt</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>WG</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Savner</surname><given-names>E</given-names></name><name><surname>Griffith</surname><given-names>EC</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Steen</surname><given-names>JA</given-names></name><name><surname>Weitz</surname><given-names>CJ</given-names></name><name><surname>Greenberg</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Brain-specific phosphorylation of MeCP2 regulates activity-dependent bdnf transcription, dendritic growth, and spine maturation</article-title><source>Neuron</source><volume>52</volume><fpage>255</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2006.09.037</pub-id><pub-id pub-id-type="pmid">17046689</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>DG</given-names></name><name><surname>Yang</surname><given-names>XK</given-names></name><name><surname>Tao</surname><given-names>SS</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Pan</surname><given-names>HF</given-names></name><name><surname>Feng</surname><given-names>CC</given-names></name><name><surname>Ye</surname><given-names>DQ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Emerging role of SIGIRR rs7396562(T/G) polymorphism in systemic lupus erythematosus in a Chinese population</article-title><source>Inflammation</source><volume>37</volume><fpage>1847</fpage><lpage>1851</lpage><pub-id pub-id-type="doi">10.1007/s10753-014-9916-z</pub-id><pub-id pub-id-type="pmid">24826913</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Postnatal neurodevelopmental disorders: meeting at the synapse?</article-title><source>Science</source><volume>302</volume><fpage>826</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1126/science.1089071</pub-id><pub-id pub-id-type="pmid">14593168</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.21735.024</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Goda</surname><given-names>Yukiko</given-names></name><role>Reviewing editor</role><aff id="aff6"><institution>RIKEN</institution>, <country>Japan</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>[Editors’ note: this article was originally rejected after discussions between the reviewers, but the authors were invited to resubmit after an appeal against the decision.]</p><p>Thank you for submitting your work entitled &quot;Deregulated IL-1 Receptor Pathway Increases MeCP2 in Neurons and Induces MeCP2- Dependent Synaptic Defects&quot; for consideration by <italic>eLife</italic>. Your article has been favorably evaluated by a Senior Editor and three reviewers, one of whom, Yukiko Goda (Reviewer #1), is a member of our Board of Reviewing Editors.</p><p>Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in <italic>eLife</italic>, at least in its present form.</p><p>While all three reviewers felt that the findings are interesting and novel, some of the data are not sufficiently compelling to support the major conclusions. Given that an extensive revision would be required to fully address the specific concerns raised by the reviewers, we are returning the manuscript to you. However, we encourage you to resubmit the work as a new manuscript if you can provide data that strongly support the hypothesis.</p><p><italic>Reviewer #1:</italic> </p><p>Here Tomasoni et al. explore the relationship between inflammation and brain function by focusing on IL-1R8 and characterizing the defects in synaptic functions in IL-1R8 KO neurons. The observed alterations in spine morphology, density and LTP in IL-1R8 KO neurons could be restored by interfering with IL-1R or by inhibiting mTOR/PI3K/Akt pathway. Similarly, downregulation of MeCP2 can reverse the synaptic defects in IL-1R8 KO neurons, suggesting that IL-1R signaling pathways controls the level of MeCP2 expression to affect synapse function and cognition. The authors also show that impaired cognitive performance of in IL-1R8 KO mice could be attenuated by blocking IL-1 activity as tested for the novel place object recognition test. Altogether, the topic is timely and the main findings are interesting. However, in the present manuscript, several key controls are missing, which make it difficult to fully interpret the data as shown. The interaction between IL-1R8 and IL-1R1, and how their signaling is related to MeCP2 expression level needs to be better characterized.</p><p>1) <xref ref-type="fig" rid="fig3">Figure 3</xref>: Interestingly, in panel B, treatment of wild type neurons with IL-1Ra blocks the increase in mushroom spines associated with LTP induction, such that IL-1R could apparently act positively in supporting LTP when IL-1R8 expression is not perturbed. To fully interpret this result, images should be shown in panel A, and the control or LTP induction in wild type neurons treated with IL1-Ra should be included for PSD95 puncta and mEPSC amplitude and frequency analysis.</p><p>2) <xref ref-type="fig" rid="fig4">Figure 4</xref>: Following from the point above, it would be helpful to compare also how the transcriptome landscape changes in wild type animals upon treatment with IL-1Ra (Anakinra).</p><p>3) <xref ref-type="fig" rid="fig5">Figure 5</xref>: Rather than simply reversing the decrease in the density of mushroom spines and PSD95 puncta to wild type controls, treatment of IL-1R8 KO neurons with inhibitors of mTOR/PI3K/Akt signaling promotes a robust increase in these parameters. How do such effects compare to the effects of these inhibitors on wild type neurons? Do they interact with the blockade of IL-1R signaling with Anakinra, which prevents the LTP-dependent increase in mushroom spines?</p><p>4) <xref ref-type="fig" rid="fig6">Figure 6H-L</xref>: Does the rescue of LTP-associated increase in mushroom spines, PSD-95 puncta, and mEPSC amplitude and frequency by knocking down MeCP2 in IL-1R8 KO neurons occlude the similar effects of IL-1Ra treatment also observed in IL-1R8 KO neurons? If MeCP2 is downstream to IL-1R, then one would expect for occlusion and this should be tested.</p><p>5) Was the MeCP2 transcript level changed in IL-1R8 KO mice and in WT mice treated with IL-1beta?</p><p>6) <xref ref-type="fig" rid="fig7">Figure 7</xref>: It would be crucial to test whether Anakira treatment in WT mice affects hippocampal spatial memory as a control. In order to claim for the rescue of cognitive deficits in IL-1R8 KO mice by blocking IL-1R signaling more compellingly, the mice should be subjected to additional behavior paradigms with or without treatment with blockers.</p><p><italic>Reviewer #2:</italic> </p><p>The current manuscript by Tomasoni et al., examines the molecular mechanisms by which IL-1R8 deficiency results in brain deficits. Through a range of genetic and pharmacological manipulations, the authors present evidence that deficiency in IL-1R8 alters spine number, mEPSC frequency and chemical LTP-induced plasticity through interleukin 1 hyper activation. However, some key data is not convincing raising questions about some of the conclusions. Although the link between IL-1R activation and MeCP2 is novel, the relevance of this finding is not supported by the data. Furthermore, there is no clear rationale for some of the experiments presented. Given these concerns, the manuscript should not be accepted in its current form.</p><p>1) Many of the images of neurons are not convincing. For example, the section of the dendrite shown under control and experimental conditions seem to come from different part of the dendritic arbour as the thickness is different (i.e. <xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig3">3</xref>, <xref ref-type="fig" rid="fig4">4</xref>, <xref ref-type="fig" rid="fig5">5</xref>, <xref ref-type="fig" rid="fig7">7</xref>, <xref ref-type="fig" rid="fig8">8</xref>). In addition, the majority of the images do not match the corresponding quantification.</p><p>2) <xref ref-type="fig" rid="fig1">Figure 1</xref>: PSD95 staining intensity is presented. It would be interesting to know the size of spines given that this is proportional to the PSD area. Furthermore, the decrease in PSD95 puncta intensity should correlate with a decrease in mEPSC amplitude, which is not seen in this experiment. The authors should provide an explanation for this.</p><p>3) In <xref ref-type="fig" rid="fig2">Figure 2</xref>, the authors examined vGlut1 (presynaptic marker) area in the IL1R8-/- mouse. These images are extremely poor and unclear. They do not seem to come from a confocal image.</p><p>4) <xref ref-type="fig" rid="fig1">Figure 1</xref>: The traces of electrophysiological recordings do not reflect the graphs presented. For example, <xref ref-type="fig" rid="fig1">Figure 1G</xref> shows a frequency of about 6Hz (based on the number of events depicted in the traces) yet the graph indicates a frequency of 1.2Hz.</p><p>5) The amplitude of EPSCs is not homogenously presented. For example, <xref ref-type="fig" rid="fig1">Figure 1</xref> shows a cumulative probability graph, <xref ref-type="fig" rid="fig3">Figures 3</xref>, <xref ref-type="fig" rid="fig5">5</xref> and <xref ref-type="fig" rid="fig8">8</xref> are normalised (but not stated as such) and <xref ref-type="fig" rid="fig4">Figure 4</xref> shows raw values. Consistency is required.</p><p>6) <xref ref-type="fig" rid="fig4">Figure 4</xref>: Pharmacological or genetic rescue experiments show an overshooting effect (increase above control condition) see <xref ref-type="fig" rid="fig4">Figures 4 B, C</xref> and E. Does it mean that the IL-1R -/- has an effect on its own?</p><p>7) The transcriptome analyses were done in cortical neurons but all the conclusions are based on the hippocampus. The data should be taken with caution.</p><p>8) The authors use several drugs (like rapamycin, LY or Anakinra) to rescue the phenotypes but they don't show the effect of these drugs alone preventing solid conclusion.</p><p>9) A rescue of the Mecp2 shRNA is required. To conclude that Mecp2 is involved in the in vivo phenotype of IL-1R8-/- mice, the authors should knock-down Mecp2 and perform behaviour experiments.</p><p>10) As the authors propose that defects in IL1-R8 deficient mice are due to hyperactivity of IL pathway, it would be interesting to examine IL1 level in this KO mouse.</p><p><italic>Reviewer #3:</italic> </p><p>This study by Tomasoni et al. reports the role of IL-1 receptor pathway in the regulation of excitatory synapses through MeCP2 regulation. In support of this conclusion, the authors provide evidence supporting that IL-1R8 antagonizes the IL-1R pathway, which negatively regulates excitatory synapse density and LTP through upregulation of MeCP2. The authors use various approaches including dissociated neuron culture, immunofluorescence staining, electrophysiology, pharmacology, and knockdown. This manuscript is a comprehensive in the experimental designs, and the data are largely convincing. Particularly novel findings seem to include that IL-1R8 negatively regulates IL-1R to promote excitatory synapses, and that MeCP2 negatively regulates excitatory synapses by acting downstream of the IL-1R-mTOR pathway.</p><p>1) <xref ref-type="fig" rid="fig7">Figure 7</xref> shows that the mTOR pathway acts downstream of IL-1R8. Are the protein levels or activity (phosphorylation) of mTOR pathway proteins increased in the IL-1R8-mutant mice? If so, is the mTOR pathway suppressed in anakinra-treated IL-1R-mutant mice?</p><p>[Editors’ note: what now follows is the decision letter after the authors submitted for further consideration.]</p><p>Thank you for resubmitting your work entitled &quot;Lack of IL-1R8 in neurons causes hyperactivation of IL-1 receptor pathway and induces MECP2-dependent synaptic defects&quot; for further consideration at <italic>eLife</italic>. Your revised article has been favorably evaluated by Jonathan Cooper (Senior Editor) and the Reviewing Editor.</p><p>The manuscript has been significantly improved with new experiments and extensive editing of the text. However, one remaining issue needs to be addressed before acceptance, as outlined below:</p><p><xref ref-type="fig" rid="fig7">Figure 7C, E</xref>. Why are immunofluorescence signals for MAP2 (panel C) and beta3 tubulin (panel D) considerably brighter in IL-1R8KO/treatment conditions compared to WT? This raises concerns about the quantification and comparison of MeCP2 signal intensity across conditions if images for different experimental conditions have been captured under different settings.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.21735.025</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>[Editors’ note: the author responses to the first round of peer review follow.]</p><p><italic>Reviewer #1:</italic> </p><p><italic>[…] 1) <xref ref-type="fig" rid="fig3">Figure 3</xref>: Interestingly, in panel B, treatment of wild type neurons with IL-1Ra blocks the increase in mushroom spines associated with LTP induction, such that IL-1R could apparently act positively in supporting LTP when IL-1R8 expression is not perturbed. To fully interpret this result, images should be shown in panel A, and the control or LTP induction in wild type neurons treated with IL1-Ra should be included for PSD95 puncta and mEPSC amplitude and frequency analysis.</italic> </p><p>To address whether IL-1R acts positively in supporting LTP when IL-1R8 expression is not perturbed, wild type neurons were treated with IL1-Ra and examined for mushroom density, PSD95 puncta and mEPSC amplitude and frequency with or without LTP, as required by the reviewer. The results indicate that treated neurons display increased PSD95-positive puncta density as well as increased mEPSC amplitude and frequency. No potentiation of any of these parameters occurs after application of the LTP protocol, indicating inability to undergo plasticity. All these results are now included in the new <xref ref-type="fig" rid="fig4">Figure 4</xref> (panels A-F). Furthermore, in line with these observations, neurons genetically devoid of the IL-1 receptor (IL-1R), similarly to wt neurons treated with IL-1Ra, were unable to undergo plasticity phenomena, as indicated by the lack of increase of either mushroom spines after LTP induction (results added as numerical data in the subsection “Defects in structure and function of IL-1R8 KO neurons are reversed by blocking IL-1 receptor activity”). Therefore, either pharmacological or genetic silencing of IL-1R is per sesufficient to alter dendritic spine morphology and plasticity. These data confirm previous literature evidence showing that blocking IL-1 receptors with IL-1ra impairs the maintenance of LTP (Schneider et al., 1998, Coogan et al., 1999; Avital et al., 2003; Costello et al. 2011). Images of WT neurons have been added to panel A of new <xref ref-type="fig" rid="fig4">Figure 4</xref>, as required by the reviewer.</p><p><italic>2) <xref ref-type="fig" rid="fig4">Figure 4</xref>: Following from the point above, it would be helpful to compare also how the transcriptome landscape changes in wild type animals upon treatment with IL-1Ra (Anakinra).</italic> </p><p>We have collected the material and sent it to the company for analysis. The results are not back yet and, however, they will need to be deeply analyzed, thus requiring few more months before being available. However, based on the functional evidences obtained in wt neurons exposed to IL-1Ra (new <xref ref-type="fig" rid="fig4">Figure 4</xref>) and in IL-1R KO neurons (numerical data added in the subsection “Defects in structure and function of IL-1R8 KO neurons are reversed by blocking IL-1 receptor activity”) and in consideration of the behavioral defects of wt mice treated with anakinra, which we have now added to the revised manuscript (new <xref ref-type="fig" rid="fig10">Figure 10</xref>), we can easily predict that the treatment with IL-1Ra will change the transcriptome landscape in wt mice. We would like to focus on this specific issue in a future research, given that a new study will be anyway necessary to provide a full description of the genes found to be changed upon IL-1R hyperactivation (reported in <xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><p><italic>3) <xref ref-type="fig" rid="fig5">Figure 5</xref>: Rather than simply reversing the decrease in the density of mushroom spines and PSD95 puncta to wild type controls, treatment of IL-1R8 KO neurons with inhibitors of mTOR/PI3K/Akt signaling promotes a robust increase in these parameters. How do such effects compare to the effects of these inhibitors on wild type neurons? Do they interact with the blockade of IL-1R signaling with Anakinra, which prevents the LTP-dependent increase in mushroom spines?</italic> </p><p>We have now added to the manuscript a novel figure illustrating the density of mushroom spines and postsynaptic puncta in wt neurons treated with inhibitors of mTOR/PI3K/Akt (new <xref ref-type="fig" rid="fig6">Figure 6</xref>). The results indicate that wt neurons exposed to the different inhibitors display an increase in spine and postsynaptic marker density. These data reveal that endogenous activation of mTOR/PI3K/Akt pathways is required for correct spine morphogenesis. This consideration has been added to the subsection “L-1R effects on hippocampal synapses are mediated by the PI3K/AKT/mTOR pathway”. This is in agreement with the evidence that physiological activation of IL-1R is required for spine morphogenesis and plasticity (see answer to point 1) and may explain why, rather than simply reversing the decrease in the density of mushroom spines and postsynaptic puncta to wild type controls, treatment of IL-1R8 KO neurons with inhibitors of mTOR/PI3K/Akt signaling promotes an increase in these parameters. The very poor health of neurons exposed to IL-1Ra together with inhibitors of mTOR/PI3K/Akt pathway hampered the possibility to examine the effects of their simultaneous presence.</p><p><italic>4) <xref ref-type="fig" rid="fig6">Figure 6H-L</xref>: Does the rescue of LTP-associated increase in mushroom spines, PSD-95 puncta, and mEPSC amplitude and frequency by knocking down MeCP2 in IL-1R8 KO neurons occlude the similar effects of IL-1Ra treatment also observed in IL-1R8 KO neurons? If MeCP2 is downstream to IL-1R, then one would expect for occlusion and this should be tested.</italic> </p><p>We performed the experiments required by the reviewer and found that, by applying the two treatments together, LTP was only partially restored, at difference with neurons where only IL-1Ra was applied. See <xref ref-type="fig" rid="fig11">Author response image 1</xref>.<fig id="fig11" position="float"><object-id pub-id-type="doi">10.7554/eLife.21735.020</object-id><label>Author response image 1.</label><caption><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.020">http://dx.doi.org/10.7554/eLife.21735.020</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21735-resp-fig1-v1"/></fig></p><p>However, given that the results of this experiment are not easy to interpret, we attempted to provide a more direct answer to the reviewer’s question of whether MeCP2 is downstream to IL-1R, by pharmacologically or genetically silencing IL-1R and quantifying MeCP2 expression. We show in the revised manuscript that application of IL-1Ra to wt neurons results in a reduction of MeCP2 levels (new <xref ref-type="fig" rid="fig7">Figure 7D</xref>); also MeCP2 levels are significantly lower in both hippocampus and cortex of mice lacking IL-1R KO, compared to wt (results of WB quantification added as numerical values in the text, subsection “The transcriptional regulator MeCP2 mediates the alterations in spine morphogenesis, synaptic transmission and synaptic plasticity observed in IL-1R8 KO hippocampal neurons”). These data further support the view that MeCP2 is downstream to IL-1R.</p><p><italic>5) Was the MeCP2 transcript level changed in IL-1R8 KO mice and in WT mice treated with IL-1beta?</italic> </p><p>The MeCP2 transcript levels are not changed in IL-1R8 KO mice, suggesting that the effects on MeCP2 occur at translational and not transcriptional level. This information, including the numerical data showing that, is now reported in the revised manuscript (subsection “The transcriptional regulator MeCP2 mediates the alterations in spine morphogenesis, synaptic transmission and synaptic plasticity observed in IL-1R8 KO hippocampal neurons”).</p><p><italic>6) <xref ref-type="fig" rid="fig7">Figure 7</xref>: It would be crucial to test whether Anakira treatment in WT mice affects hippocampal spatial memory as a control. In order to claim for the rescue of cognitive deficits in IL-1R8 KO mice by blocking IL-1R signaling more compellingly, the mice should be subjected to additional behavior paradigms with or without treatment with blockers.</italic> </p><p>To address the reviewer’s request, we tested IL-1R8 KO mice for the Morris water maze and the rewarded T maze. In line with the concept that alternation, either rewarded or spontaneous, detects hippocampal dysfunction even better than the Morris water maze (reviewed in Deacon et al., 2006), no significant defects of IL-1R8 KO mice in the Morris test were apparent, while an impairment of spatial memory was detected in the rewarded T-maze task. Treatment with Anakinra ameliorated the performance. A novel figure (<xref ref-type="fig" rid="fig10">Figure 10</xref>) has been produced with a complete behavioral characterization. The new figure also includes the effect of Anakinra in wt mice tested for novel place object recognition, as required by the reviewer. The description of these results is included subsection “Inhibition of IL-1β receptor by Anakinra rescues behavioral defects” of the Results section.</p><p><italic>Reviewer #2:</italic> </p><p><italic>The current manuscript by Tomasoni et al., examines the molecular mechanisms by which IL-1R8 deficiency results in brain deficits. Through a range of genetic and pharmacological manipulations, the authors present evidence that deficiency in IL-1R8 alters spine number, mEPSC frequency and chemical LTP-induced plasticity through interleukin 1 hyper activation. However, some key data is not convincing raising questions about some of the conclusions. Although the link between IL-1R activation and MeCP2 is novel, the relevance of this finding is not supported by the data. Furthermore, there is no clear rationale for some of the experiments presented. Given these concerns, the manuscript should not be accepted in its current form.</italic> </p><p>In his/her comments, the reviewer claims that “some key data are not convincing and this raises questions about some of the conclusions of our manuscript”. While this appears like a quite serious general concern, we noticed that, actually, most of the reviewer’s points relate with figure panels used as representative images. We apologize with the reviewer for the choice of our images and we provide novel panels to address his/her concerns.</p><p><italic>1) Many of the images of neurons are not convincing. For example, the section of the dendrite shown under control and experimental conditions seem to come from different part of the dendritic arbour as the thickness is different (i.e. <xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig3">3</xref>, <xref ref-type="fig" rid="fig4">4</xref>, <xref ref-type="fig" rid="fig5">5</xref>, <xref ref-type="fig" rid="fig7">7</xref>, <xref ref-type="fig" rid="fig8">8</xref>). In addition, the majority of the images do not match the corresponding quantification.</italic> </p><p>We apologize with the reviewer for the not convincing images. We believe that this is partly due to the fact that the pdf generated by the system and sent to the reviewers is of low quality and we would ask the Editorial Office to please send the figures to the reviewers in a different format, if possible. However, in order to answer the reviewer’s criticism, we have now changed most of the images of the revised manuscript, choosing more homogeneous fields, with a similar thickness of the dendritic arbour and paying more attention in choosing fields which match better the corresponding quantification. The revised figures which contain all or most novel panels are the following: <xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4">Figure 4G</xref>, <xref ref-type="fig" rid="fig6">Figure 6A</xref>.</p><p><italic>2) <xref ref-type="fig" rid="fig1">Figure 1</xref>: PSD95 staining intensity is presented. It would be interesting to know the size of spines given that this is proportional to the PSD area. Furthermore, the decrease in PSD95 puncta intensity should correlate with a decrease in mEPSC amplitude, which is not seen in this experiment. The authors should provide an explanation for this.</italic> </p><p>We wish to point out that the PSD-95 staining intensity quantitation in original <xref ref-type="fig" rid="fig1">Figure 1</xref> referred to the WB analysis of wt and IL-1R8 KO cultured neurons. Concerning PSD-95 puncta, our original manuscript reported only their density (number of puncta/micron length of parent dendrite) assessed by confocal analysis. To meet the reviewer’s request, we are now providing a quantitation of spine width and PSD-95 puncta area, both of which are significantly reduced in IL- 1R8 KO neurons (new <xref ref-type="fig" rid="fig1">Figure 1D and F</xref>, subsection “Altered synaptic architecture and function in IL-1R8 KO hippocampal neurons” of Results). Concerning the reviewer’s statement that “the decrease in PSD95 puncta intensity should correlate with a decrease in mEPSC amplitude”, several reports in literature indicate that, in fact, mEPSC frequency, and not amplitude, is impacted by tuning the levels of postsynaptic proteins, like PSD-95, PSD-93, SAP102 or GluA2 (Sun and Turrigiano, J Neurosci 2011; Saglietti et al. Neuron 2007). In particular, Sun and Turrigiano have shown that overexpression of PSD-95 increases mEPSC frequency, but not amplitude, and that knockdown of PSD-95 does not affect mEPSC amplitude. Our data are therefore in line with already published evidence.</p><p><italic>3) In <xref ref-type="fig" rid="fig2">Figure 2</xref>, the authors examined vGlut1 (presynaptic marker) area in the IL1R8-/- mouse. These images are extremely poor and unclear. They do not seem to come from a confocal image.</italic> </p><p>We apologize with the reviewer for the poorness of the images in <xref ref-type="fig" rid="fig2">Figure 2</xref>. As mentioned before, we believe that this may be, at least in part, the consequence of the bad quality of the pdf file generated by the system. However, we are now providing a better quality, alternative image for <xref ref-type="fig" rid="fig2">Figure 2C</xref>.</p><p><italic>4) <xref ref-type="fig" rid="fig1">Figure 1</xref>: The traces of electrophysiological recordings do not reflect the graphs presented. For example, <xref ref-type="fig" rid="fig1">Figure 1G</xref> shows a frequency of about 6Hz (based on the number of events depicted in the traces) yet the graph indicates a frequency of 1.2Hz.</italic> </p><p>Following the reviewer’s notice, we have realized that in fact the traces we have provided do not reflect the exact average frequency reported by the quantitation. While we point out that electrophysiological traces are taken as representative and are meant to make a qualitative point, which is then quantified in the histograms, we have now substituted the electrophysiological traces, choosing examples which display the exact average frequency emerging from the quantitative analysis (see new <xref ref-type="fig" rid="fig1">Figure 1I</xref>, old <xref ref-type="fig" rid="fig1">Figure 1G</xref>).</p><p><italic>5) The amplitude of EPSCs is not homogenously presented. For example, <xref ref-type="fig" rid="fig1">Figure 1</xref> shows a cumulative probability graph, <xref ref-type="fig" rid="fig3">Figures 3</xref>, <xref ref-type="fig" rid="fig5">5</xref> and <xref ref-type="fig" rid="fig8">8</xref> are normalised (but not stated as such) and <xref ref-type="fig" rid="fig4">Figure 4</xref> shows raw values. Consistency is required.</italic> </p><p>We now show both cumulative and normalized amplitudes in <xref ref-type="fig" rid="fig1">Figure 1K</xref>. In the case of LTP, in order to make the figure more comprehensible to the readers, only the normalized frequency and amplitude are shown, as usually displayed in literature (Lu et al., 2001; Fortin et al., 2010). We have now specified in the figure legend and on the y axis when normalization was performed (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref>; <xref ref-type="fig" rid="fig4">Figure 4E and F</xref>).</p><p><italic>6) <xref ref-type="fig" rid="fig4">Figure 4</xref>: Pharmacological or genetic rescue experiments show an overshooting effect (increase above control condition) see <xref ref-type="fig" rid="fig4">Figures 4 B, C</xref> and E. Does it mean that the IL-1R -/- has an effect on its own?</italic> </p><p>We thank the reviewer for raising this point, which has now been addressed. The revised version of the manuscript reports the effects of all pharmacological treatments (IL-1Ra and all the inhibitors of mTOR/PI3K/Akt signaling) in wt neurons (see new <xref ref-type="fig" rid="fig4">Figure 4</xref> and new <xref ref-type="fig" rid="fig6">Figure 6</xref>). These data indicate that pharmacological blockade of either IL-1R or mTOR/PI3K/Akt pathway is per se sufficient to alter dendritic spine morphology and plasticity (sentences added in the subsections “Defects in structure and function of IL-1R8 KO neurons are reversed by blocking IL-1 receptor activity” and “IL-1β treatment and IL-1R8 deficiency trigger overlapping gene programs related to hippocampal development and synaptic transmission”). See also answers to points 1 and 3 of reviewer 1.</p><p><italic>7) The transcriptome analyses were done in cortical neurons but all the conclusions are based on the hippocampus. The data should be taken with caution.</italic> </p><p>We thank the reviewer for his/her note of caution. However, we wish to point out that the WB analysis of MeCP2 levels was originally performed also in the cortex in IL-1R8 KO mice, with or without IL-1Ra treatment, with similar results (<xref ref-type="fig" rid="fig9">Figure 9E, F and G</xref> of the original manuscript, now <xref ref-type="fig" rid="fig9">Figure 9F, G and H</xref>). In order to further meet the reviewer’s point, we added to the revised manuscript the confocal quantitation of MeCP2 levels in mice cortex and corresponding images (new <xref ref-type="fig" rid="fig9">Figure 9A, D and E</xref>).</p><p><italic>8) The authors use several drugs (like rapamycin, LY or Anakinra) to rescue the phenotypes but they don't show the effect of these drugs alone preventing solid conclusion.</italic> </p><p>The revised version of the manuscript reports the quantitation of the effects of all drugs in wt neurons (new <xref ref-type="fig" rid="fig4">Figure 4</xref> for IL-1Ra and new <xref ref-type="fig" rid="fig6">Figure 6</xref> for LY, wortmannin and rapamycin).</p><p><italic>9) A rescue of the Mecp2 shRNA is required. To conclude that Mecp2 is involved in the</italic> in vivo <italic>phenotype of IL-1R8-/- mice, the authors should knock-down Mecp2 and perform behaviour experiments.</italic> </p><p>In our manuscript, we have shown that MeCP2 is involved in the neuronal synaptic phenotype, while we have never claimed that MeCP2 is involved in the in vivo, behavioral phenotype. Obtaining a direct evidence of this would be in fact very challenging. The viral siRNA intrahippocampal injection allows access only to the dorsal hippocampus leaving the ventral one untouched. Due to the limited virus spreading upon intraparenchymal injection, a relatively low number of cells is transduced, thus failing to achieve a sufficient gene correction for behavioral studies (Parr-Brownlie et al., Front Mol Neurosci 2015). We already experienced this limitation in our previous studies (Fossati et al., Cell Death and Differentiation 2015). Also, MeCP2 is widely involved in several neuronal functions, and even small variations of MeCP2 results per se in robust behavioral deficits (see for example Chao &amp; Zoghbi Nature Neuroscience, 2012; Samaco et al., 2013), implying that only physiological levels of MeCP2 can guarantee the proper brain functioning. Finely controlling levels of MeCP2 expression in vivo using the above strategy is not attainable. In order to avoid possible misunderstandings and make clear that we cannot conclude that Mecp2 is involved in the in vivo phenotype of IL-1R8KO mice, we have now reorganized the in vivo section of our manuscript and smoothened our conclusions further (Results and Discussion).</p><p><italic>10) As the authors propose that defects in IL1-R8 deficient mice are due to hyperactivity of IL pathway, it would be interesting to examine IL1 level in this KO mouse.</italic> </p><p>Costello et al., in their 2011 paper, have already shown that IL-1alpha but not IL-1beta is increased in IL1-R8 deficient mice.</p><p><italic>Reviewer #3:</italic></p><p><italic>[…] 1) <xref ref-type="fig" rid="fig7">Figure 7</xref> shows that the mTOR pathway acts downstream of IL-1R8. Are the protein levels or activity (phosphorylation) of mTOR pathway proteins increased in the IL-1R8-mutant mice? If so, is the mTOR pathway suppressed in anakinra-treated IL-1R-mutant mice?</italic> </p><p>From our transcriptomic analysis we know that RNA levels for mTOR are not changed in IL-1R8 KO mice brain (see <xref ref-type="fig" rid="fig12">Author response image 2</xref>).<fig id="fig12" position="float"><object-id pub-id-type="doi">10.7554/eLife.21735.021</object-id><label>Author response image 2.</label><caption><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21735.021">http://dx.doi.org/10.7554/eLife.21735.021</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21735-resp-fig2-v1"/></fig></p><p>This suggests that is the activity of the pathway likely increased in IL-1R8 KO neurons, as already reported in IL-1R8 KO T cells (Gulen et al. 2010). Consistently, rapamycin rescues the phenotypes, indicating the increased activity of the pathway in our experimental conditions.</p><p>[Editors’ note: the author responses to the re-review follow.]</p><p><italic>The manuscript has been significantly improved with new experiments and extensive editing of the text. However, one remaining issue needs to be addressed before acceptance, as outlined below:</italic> </p><p><italic><xref ref-type="fig" rid="fig7">Figure 7C, E</xref>. Why are immunofluorescence signals for MAP2 (panel C) and beta3 tubulin (panel D) considerably brighter in IL-1R8KO/treatment conditions compared to WT? This raises concerns about the quantification and comparison of MeCP2 signal intensity across conditions if images for different experimental conditions have been captured under different settings.</italic> </p><p>In order to quantify MeCP2 levels of expression, confocal images were captured using settings which were maintained strictly constant among the different experimental conditions. Sometimes, the focal plan of microtubules (stained for MAP2 or beta3 tubulin in order to provide a general picture of neuronal cells) was not coincident with the optimal focal plan used for capturing MeCP2-stained nuclei, thus resulting in apparent differences in the staining intensity of microtubules. Although the staining for microtubules is not quantified, thus excluding any possible impact on MeCP2 analysis, we agree that this inhomogeneity among different pictures may result misleading. We are grateful to the Editors for noticing this point. We have now substituted panels in <xref ref-type="fig" rid="fig7">Figure 7C and E</xref> in order to have more homogeneous pictures.</p></body></sub-article></article>